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SUMMARY 
 Lipids are necessary components of all cell membranes and are important 
both as structural elements and as modulators of cell fluidity. Several lipid 
molecular species are present in cells, including various types of phospholipids, 
cholesterols and sphingolipids. Lipids are especially important in the central 
nervous system (CNS). Homeostasis of membrane lipids in neurons and myelin 
is essential to prevent the loss of synaptic plasticity, cell death and 
neurodegeneration. Because membrane lipids are so important as structural 
components in the CNS, changes in brain lipid levels due to their increased or 
decreased synthesis or metabolism may result in homeostatic dysregulation and 
ultimately neurodegeneration. This is important because neurodegeneration is a 
characteristic component of all dementias. Inhibition of dysregulated lipid 
metabolism may confer neuroprotection. This study used a kainate-induced 
neurodegenerative model and suggests that dysregulation of two important 
membrane lipids, cholesterol and ceramide, may lead to or accelerate 
neurodegeneration and therefore may be important in the pathogenesis of 
neurodegenerative diseases. The results also indicate the neuroprotective effect 
of a lipid binding protein, apolipoprotein D (apoD). 
 The first part of the present study was carried out to elucidate alterations 
in metabolism of cholesterol, a key lipid component of the cell membrane, after 
neuronal injury induced by the excitotoxin, kainate. Increased immunolabeling of 
the oxysterol biosynthetic enzyme, cholesterol 24-hydroxylase, was observed in 
 XV
the rat hippocampus after kainate lesions. This was accompanied by increased 
levels of cholesterol, 24-hydroxycholesterol (product of cholesterol 24-
hydroxylase enzymatic activity) and 7-ketocholesterol in homogenates of the 
degenerating hippocampus, as detected by gas chromatography / mass 
spectrometry (GC/MS). Hippocampi from rats or organotypic slices that had been 
treated with kainate plus lovastatin showed significantly lower levels of 
cholesterol, 24-hydroxycholesterol, and 7-ketocholesterol, compared to those 
treated with kainate only. Lovastatin also modulated hippocampal neuronal loss 
after kainate treatment, in vivo and in vitro. The level of 24-hydroxycholesterol 
detected in vivo after kainate treatment ( > 50 µM) was found to be neurotoxic in 
hippocampal slice cultures. The above results suggest that increased brain 
cholesterol biosynthesis and oxysterol formation play a role in propagation of 
neuronal death after kainate injury and brain permeable statins such as lovastatin 
could have a neuroprotective effect by limiting the levels of oxysterols in brain 
areas undergoing neurodegeneration. 
 The second part of the study focused on changes in metabolism of 
ceramide, another major lipid component of the cell membrane, after kainate-
induced neuronal injury. Ceramide is involved in many cellular events including 
apoptosis, growth arrest, differentiation, senescence, mediating an immune 
response, oxidative stress responses, and nitric oxide signaling. An increase in 
ceramide species has recently been demonstrated by lipidomic analysis of the rat 
hippocampus after kainate-induced excitotoxic injury. In addition, increased 
expression of serine palmitoyltransferase (SPT), the first enzyme in the ceramide 
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biosynthetic pathway was observed in reactive astrocytes of the hippocampus 
after kainate injections. The increase in enzyme expression was paralleled by 
increased SPT enzyme activity in the hippocampus at two week post-kainate 
injection. In vitro studies showed that treatment of hippocampal slice cultures 
with SPT inhibitor ISP-1 (myriocin) or L-cycloserine modulated increases in 16:0, 
18:0 and 20:0 ceramide species and partially reduced kainate-induced cell death. 
The above findings indicate a role of SPT in ceramide increase after kainate 
injury. They also suggest that increased SPT activity and biosynthetic ceramide 
might contribute to neuronal injury after kainate excitotoxicity. 
 The third part of this study was carried out to examine potential effects of 
a lipid binding protein, apoD on neuronal survival after kainate injury. ApoD 
belongs to the lipocalin superfamily of transporter proteins that carry various 
small hydrophobic ligands, such as arachidonic acid and cholesterol. A marked 
increase of apoD has been shown in the rat hippocampus after neuronal injury 
induced by kainate. Addition of purified human apoD to kainate treated 
hippocampal slice cultures resulted in reduction in neuronal death, and 
modulation of increased arachidonic oxidation product (F2-isoprostane), 
cholesterol, and cholesterol oxidation product (24-hydroxycholesterol and 7-
ketocholesterol) levels in the kainate treated slices. The results showed that the 
neuroprotective effect of apoD may be due to its ability to bind arachidonic acid, 
thus resulting in reduction of lipid peroxidation products, and its ability to prevent 
the formation of neurotoxic cholesterol oxidation products by regulating the 
cholesterol metabolism. Fibroblasts from apoD knockout mice showed increased 
 XVII
F2-isoprostane and 7-ketocholesterol levels after hydrogen peroxide induced 
oxidative stress, suggesting that this lipocalin may be an important antioxidant 
protein in the brain. 
 Taken together, the above findings indicate that deleterious changes in 
lipid homeostasis and signaling may be a key factor in the onset and progression 
of pathologies of the brain. They also provide clues to the development of 
pharmaceutical strategies to treat neurodegenerative disorders by regulating the 
lipid metabolism, in which cholesterol and ceramide metabolic enzyme, and 
apoD may play important roles. 
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1. General introduction 
 Lipids are important for the brain, as it contains the second highest 
concentration of lipids exceeded only by adipose tissue (Adibhatla et al. 2006). 
Besides this quantitative importance, lipids in the brain show bewildering diversity 
(Wenk 2005). A large number of proteins are associated with synaptic 
membranes. In addition, a number of key enzymes involved in the metabolism of 
lipids have been discovered and characterized in nerve terminals (Cremona and 
De Camilli 2001).  
 The majority of cellular lipids are organized in membranes (van Meer 
2001). This is a fluid patchwork of lipid and protein molecules in constant motion. 
Carbohydrates attached to the proteins and phospholipids form glycoproteins 
and glycolipids (Alberts et al. 1994). The most abundant membrane lipids are the 
phospholipids (PPs). In addition, sphingolipids form a static, solid membrane, 
which is fluidized by cholesterol (reviewed in Fahy et al. 2005).  
 Functional responses of ion channels, synaptic function and cellular 
signaling cascades may be affected by the lipid composition of the cell 
membrane. It has been suggested that neuronal cell function can be modified to 
meet physiologic demand through appropriate alterations in the type, nature and 
organization of lipids in specific cell membrane compartments (reviewed in Gross 
et al. 2005).  
 Deleterious changes in lipid homeostasis are viewed as important factors 
in the pathogenesis of many neurological disorders such as Alzheimer’s disease 
(AD) (Cutler et al. 2004b), Parkinson’s disease (PD) (Sharon et al. 2003), 
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Niemann–Pick disease type C disease (NPC) (Sturley et al. 2004), and cerebral 
ischemic injury (Farooqui et al. 2004; Rao et al. 2000; Nakane et al 2000). 
 
2. Cell lipids 
2. 1. Phospholipids 
2. 1. 1. Structure and functions 
 Phospholipids are composed of a glycerol (3 carbon chain) backbone with 
fatty acids esterified at the sn-1 and sn-2 positions (Fig. 1). The fatty acids can 
vary in length from 14 to 22 carbons and can have from 0 to 6 double bonds 
(Schiller et al. 2004). The sn-3 position has a phosphate group attached to a 
polar head group (Fig. 1). The amphiphilic nature of phospholipids, owing to the 
polar head group and non-polar fatty acid tails, causes them to come together as 
a bilayer (reviewed in Peterson and Cummings 2006). There are several groups 
of phospholipids based on the polar head group: choline glycerophospholipids 
(PC), ethanolamine glycerophospholipids (PE), inositol glycerophospholipids (PI), 
glycerol glycerophospholipids (PG) or serine glycerophospholipids (PS) (Paltauf 
1994; Farooqui et al. 2000a). The cell membrane has an asymmetrical 
distribution of phospholipids. The outer leaflet is mainly composed of PC while 
PE and PS are the primary phospholipids found in the inner cytosolic membrane 
(Bevers et al.1998). Besides the above glycerophospholipids, membranes also 
contain plasmalogens (PlsC and PlsE), which are glycerophospholipids of neural 
membranes containing vinyl ether bonds (Farooqui and Horrocks 2001). 
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Figure 1. Basic structure of phospholipids. Consists of a glycerol backbone with fatty acids (R1 
and R2) linked at the sn-1 and sn-2 positions. Various polar head groups (X) link to the 
phosphate group at the sn-3 position (Peterson and Cummings 2006). 
  
 Phospholipid bilayer membranes are highly structured, dynamic and 
penetrated to varying degree by receptors, enzymes, and ion channels. The 
latter protrude differentially through the membrane or localize predominantly on 
the intracellular or extracellular membrane surface. The changes in phospholipid 
metabolism can regulate activities of membrane-bound enzymes, receptors, and 
ion channels (Farooqui and Horrocks 1985). Different pools of phospholipid 
molecular species may have different metabolic and physical properties 
depending upon their localization in different types of cell membranes (Farooqui 
et al. 2004).  
 
2. 1. 2. Phospholipids in the brain 
 Brain tissue contains relatively high amounts of phospholipids. Together 
with cholesterol and glycolipids, they represent 50–60% of the total membrane 
mass of neural membranes (Farooqui et al. 2000b). Human brain neural 
membranes contain a variety of phospholipids including PC, PE, PlsE, PS, PI, 
and sphingomyelin (Horrocks et al. 1981). PC, PlsE, and PE are major 
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phospholipid components of neural membranes in all regions. This is followed by 
sphingomyelin, which is most enriched in white matter (Söderberg et al. 1990). 
Among the membranes of the brain, myelin contains the highest content of 
phospholipids. The phospholipid composition of myelin is similar to that of white 
matter and very different from that of grey matter (Farooqui et al. 2004). 
 Neural membrane phospholipids are predominantly synthesized in the 
endoplasmic reticulum (ER). Significant synthesis of PC and PI also occurs in 
Golgi membranes (Farooqui et al. 2000a). Following synthesis, phospholipids are 
transported to membranes by phospholipid transfer-exchange proteins (Voelker 
et al. 2003). Neural membrane phospholipids are degraded by receptor-mediated 
hydrolytic process involving phospholipases (PLA), lysophospholipases (LPA), 
and lipases (Farooqui 2000b). 
 The polyunsaturated fatty acids at the sn-2 position of phospholipids are 
susceptible to free radical attack at the α-methylene carbon. The lipid 
hydroperoxides thus formed are not completely stable in vivo and, in the 
presence of iron, can further decompose to radicals that can propagate the chain 
reactions started by an initial free radical attack. Lipid hydroperoxides also 
generate aldehydes that can in turn cross-link enzymes and proteins making 
them inactive (Farooqui et al. 2000a, Halliwell 1994). 
  The damage to neural membranes induced by lipid peroxidation can 
result in the following effects: (a) changes in physicochemical properties of neural 
membranes (microviscosity) resulting in alterations in the orientation of optimal 
domains for the interaction of functional membrane proteins such as receptors, 
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enzymes, and ion-channels; (b) changes in the number of receptors and their 
affinity for neurotransmitters and drugs; and (c) inhibition of ion pumps resulting 
in changes in ion homeostasis (Farooqui et al. 2000a). 
 The presence of peroxidized phospholipids in neural membranes may also 
produce a membrane-packing defect, making the sn-2 ester bond more 
accessible to the action of PLA2. The hydrolysis of peroxidized phospholipids 
results in removal of peroxidized fatty acyl chains, which are reduced and re-
esterified. Thus, the action of PLA2 repairs and restores the physiological 
physicochemical state of neural membranes (Farooqui et al. 2000a). Healthy 
neural cells contain tight packing of phospholipids in the outer leaflet. The 
disruption of phospholipid asymmetry leads to looser phospholipid packing in the 
outer leaflet, thus allowing Ca2+ entry. The alteration in Ca2+ homeostasis and its 
short duration may lead to neuronal degeneration by the activation of PLA2 
(Farooqui et al. 2000b).  
 The activation of PLA2 releases arachidonic acid from neural membrane 
phospholipids and sets in motion an uncontrolled ‘‘arachidonic acid cascade’’. 
That includes the synthesis and accumulation of prostaglandins, leukotrienes, 
thromboxanes, and 4-hydroxy-2-nonenal (4-HNE), a peroxidized product of 
arachidonic acid. High concentration of arachidonic acid has a profound adverse 
effect on the ATP producing capacity of the brain mitochondria. It uncouples 
oxidative phosphorylation and induces efflux of Ca2+ and K+ from mitochondria 
(Katsuki and Okuda 1995). 4-HNE impairs the activities of key metabolic 
enzymes, including Na+, K+-ATPase, glucose-6-phosphate dehydrogenase, and 
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several kinases. It stimulates stress-activated protein kinases such as c-jun 
amino terminal kinase (JNK) and p38 mitogen-activated protein kinase 
(Camandola et al. 2000; Tamagno et al. 2003). The arachidonic acid cascade 
also potentiates the formation of free radicals and lipid hydroperoxides produced 
by the action of 12-lipoxygenase. The lipid hydroperoxides are known to inhibit 
reacylation of phospholipids in neuronal membranes (Zaleska and Wilso 1989). 
This inhibition may contribute to necrotic cell death in neural cells (Farooqui et al. 
2000c).  
 
2. 1. 3. Phospholipids in neurological disorders 
 Loss of phospholipids and increase in phospholipid-degradation products 
are known to occur in acute brain trauma and neurodegenerative diseases 
(Farooqui and Horrocks 1994; Pettegrew et al. 1995). Changes in phospholipids 
and stimulation of phospholipases have been reported in acute brain disorders 
such as ischemia, hypoxia, hypoglycemia, spinal cord and brain injuries 
(Farooqui and Horrocks 1991), excitotoxic models of neurodegeneration 
(Sandhya et al. 1998), and in chronic neurodegenerative diseases such as AD 
(Kanfer et al. 1986; Nitsch et al. 1992; Farooqui et al.1990; Farooqui and 
Horrocks 1991; Prasad et al. 1998), schizophrenia (Gattaz and Brunner 1996; 
Ross et al. 1999), and Huntington's disease  (HD) (Ellison et al. 1987).  
 Phospholipid degradation in brain tissue results in a decrease in content of 
essential phospholipids in neuronal and glial cell membranes, and an 
accumulation of free fatty acids, prostaglandins, lysophospholipids, and lipid 
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peroxides (Prasad et al. 1998). High concentrations of these metabolites may 
alter the physicochemical properties of neuronal and glial cell membranes and 
loss of ionic gradients due to alterations in the conformation and function of 
transmembrane ion-channels, inflammation, and oxidative stress. All these 
processes, along with compromised metabolism, may contribute to irreversible 
neural cell injury (Farooqui and Horrocks 1994; Farooqui et al. 1997; Farooqui et 
al. 2000b).  
 In ischemic injury, the glutamate-mediated neurodegeneration may be 
rapid (in days) because of the sudden lack of oxygen, quick drop in ATP, and 
alterations in ion homeostasis. Ischemic injury results in a huge increase in the 
levels of free fatty acids and a marked decrease in the phospholipid content of 
neural membranes. This is due to the stimulation of PLA2 (Edgar et al. 1982; 
Rordorf et al. 1991).  
 In chronic neurodegenerative diseases such as AD, oxygen, nutrients, and 
ATP are available to the nerve cells and ionic homeostasis is maintained to a 
limited extent. Thus the resulting neural cell injury takes several years to develop 
(Farooqui and Horrocks 1991; 1994). Neural membranes of AD patients is not 
only accompanied by increased PLA2 activities in different regions of AD brain 
compared to age matched controls (Stephenson et al. 1996; 1999), but also by 
the elevation of phospholipid degradation metabolites. This increase in 
phospholipid metabolites correlates with pathologic markers of AD such as 
neurofibrillary tangles and senile plaques (Pettegrew 1989). The aldehydic 
product of arachidonic acid metabolism, 4-HNE, co-localizes with intraneuronal 
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neurofibrillary tangles and has been suggested to contribute to the cytoskeletal 
derangement found in AD. Alterations in phospholipid metabolism may be closely 
associated with the loss of synapses and neurons in AD (Farooqui and Horrocks 
1994; Prasad et al. 1998). 
 
2. 2. Cholesterol 
2. 2. 1. Distribution and functions 
 Cholesterol is a sterol (a combination of steroid and alcohol) found in the 
cell membrane of all body tissues. It makes the membrane's fluidity- degree of 
viscosity - stable over wider temperature. It is a constituent of the myelin sheath 
in nerves and present in all plasma lipoproteins. The requirement for cholesterol 
is much greater in cells dividing or growing rapidly than in those in a resting state. 
It is a component of lipid rafts in the plasma membrane and implicated in cell 
signalling processes. Cholesterol reduces the permeability of the plasma 
membrane to proton and sodium ions (Haines 2001). It is also essential for the 
structure and function of caveolae and clathrin-coated pits, including the 
caveolae-dependent endocytosis and clathrin-dependent endocytosis (Pichler 
and Riezman 2004).   
 Cholesterol plays an important role with respect to the physical structure 
of the cell membrane. Another important role of cholesterol is its interaction with 
membrane proteins and this interaction has been described in both neuronal and 
non-neuronal cells (Krueger and Papadopoulos 1990; Michelangeli 1990). In 
both erythrocytes (Schroeder et al. 1991) and synaptic plasma membranes 
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(Wood et al. 1989a), cholesterol accounts for over 40 mol% (40 membrane 
cholesterol molecules/100 cholesterol molecules in a lipid unit) of total 
cholesterol lipid. The distribution of cholesterol in the plasma membrane is 
asymmetric and lateral, and it is usually located in different pools or domains 
(Schroeder et al. 1988; Wood et al. 1993; Wood et al. 1999). Modification of 
membrane cholesterol content in different pools or domains can alter membrane 
fluidity, lipid packing and interdigitation, as well as membrane protein functions 
(Yeagle 1992). 
 The brain is the cholesterol-rich organ in the human body (Cook 1958). 
The central nervous system accounts for only 2% of the whole body mass but 
contains almost a quarter of the unesterified cholesterol (~ 15 g) present in the 
whole individual (Dietschy and Turley 2001). Brain cholesterol is found in the 
plasma membranes of glial cells, in neuronal membranes, and in the myelin 
sheaths (Spady and Dietschy 1983). Cholesterol is important for the function of 
this organ as a constituent of myelin and cell membranes, and has also been 
shown to modulate the stability of microtubules in cultured neurons, as well as 
neuronal functions such as endocytosis and antigen expression (Fan et al. 2002).  
 Cholesterol plays an important role in the normal function of the brain. 
Modification of cholesterol domains can alter the activity of certain intergral 
proteins, and such domains may be important to neuronal functions, such as ion 
transport and receptor function. For example, a reduction in the content of 
cholesterol in the membranes produces a loss in sodium dependent γ-
aminobutyric acid (GABA) uptake in synaptic plasma membrane and 
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synaptosomes (North and Fleischer 1983). The uptake is restored by the addition 
of cholesterol. The functions of other proteins, including Na+-K+ ATPase (Yeagle 
et al. 1988; Incerpi et al. 1992) and Ca2+-Mg2+ ATPase (Cornea and Thomas 
1994), are also affected by alterations in the content of membrane cholesterol.  
 The inner leaflet of synaptic plasma membranes contains over 85% of the 
total plasma membrane cholesterol (Wood et al. 1990). It is well known that 
membrane fluidity is inversely correlated with the cholesterol-to-phospholipid 
ratio and that the increased ratio reduces fluidity. As a result, the inner leaflet that 
contains almost seven times as many cholesterol levels as those of outer leaflet 
is markedly less fluid compared to the outer leaflet (Wood et al. 1990). Factors 
such as ethanol (Schroeder et al. 1988; Wood et al. 1989b) and increasing 
temperature (Schroeder et al. 1988) have a greater effect on the fluidity of the 
outer leaflet. In vivo, the synaptic plasma membrane cholesterol can also be 
modified by specific factors (Wood et al. 1999). A mouse model of chronic 
ethanol consumption showed approximately a two-fold increase in cholesterol in 
outer leaflet, but no change in total cholesterol compared with control groups 
(Wood et al. 1989b). 
 Thus far, little is known about the mechanisms that regulate cholesterol 
domains and their contribution to neuronal homeostasis. Evidence shows that 
changes in sterol carrier protein-2 (SCP-2), brain fatty acid binding protein (B-
FABP), and heart fatty acid binding protein (H-FABP) in the brain are associated 
with modification of the transbilayer distribution of cholesterol and fluidity in the 
synaptic plasma membrane of chronic ethanol consumption mice and aged mice 
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(Myers-Payne et al. 1996a, b; Pu et al. 1999). In addition, other factors 
associated with cholesterol metabolism such as apolipoproteins, their receptors, 
and sphingomyelin could also play a role in regulation of the distribution of 
cholesterol content in the plasma membrane. This is supported by the 
observation that the cholesterol level of the outer leaflet is two-times higher in the 
synaptic plasma membrane of apoE-deficient and low-density lipoprotein 
receptor (LDL-R) deficient mice than that in controls (Igbavboa et al. 1997). 
These differences in cholesterol distribution are not accounted for by difference 
in the total amount of membrane cholesterol. 
 
 2. 2. 2. Cholesterol in the brain 
 2. 2. 2. 1. Cholesterol synthesis and elimination in the brain 
 A large number of studies have established that there is little uptake of 
cholesterol from the bloodstream into the brain, and that brain cholesterol is 
derived mostly from de novo synthesis (Fig. 2, Wilson 1970; Kabara 1973; 
Jurevics and Morell 1995). The brain has a high rate of cholesterol synthesis 
during late fetal and early neonatal life (Ness et al. 1979; Dietschy et al. 1983; 
Cavender et al. 1995). This declines rapidly at about the time of weaning, and 
remains low throughout adulthood (Ness et al. 1979; Dietschy et al. 1983; Spady 
and Dietschy 1983). The high rate of cholesterol synthesis in early life is 
essential to ensure normal growth and development of the brain. In patients with 
Smith-Lemli-Optiz syndrome, an autosomal recessive disorder, a major block in 
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the terminal step of the cholesterol biosynthesis pathway results in severe mental 
retardation and multiple birth defects (Tint et al. 1994).  
 
Figure 2. Synthetic and metabolic pathways for cholesterol (Buhaescu and Izzedine 2007) 
 The rate of cholesterol biosynthesis was reported to be only ~ 0.1% of 
newly synthesized cholesterol in adult monkey brains. The biosynthetic rates 
were assessed by measuring the velocity at which [3H] water was incorporated 
into digitonin-precipitable sterols (DPS) in the intact animal. When expressed as 
a percentage of total body synthesis, the whole brain of the monkey contained 
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1% of the [3H] DPS and the liver contained 40% of [3H] DPS (Spady and 
Dietschy 1983). In humans, therefore it is estimated that only 1-2 mg of 
cholesterol will be synthesized each day. Nevertheless, a study that measures 
the absolute rate of cholesterol synthesis in the brain of neonatal rats shows the 
amount of cholesterol synthesized locally is sufficient to fully account for all the 
brain cholesterol deposition that occurs during that stage of their development 
(Jurevics et al. 1997; Turley et al. 1981). Based on in vitro experiments, it is 
expected that the half-life of brain cholesterol in rat brain slices is about 6 months 
(Andersson et al. 1990). 
 The highest concentration of cholesterol is found in myelin in the brain. 
The source of cholesterol for myelination is mainly by local synthesis (Snipes and 
Suter 1997). In vitro studies have confirmed that oligodendrocytes have the 
ability to synthesize cholesterol from acetoacetate and glucose (Koper et al. 
1984). However, it appears that oligodendrocytes may not be the only cell type in 
the brain that can synthesize cholesterol. An increase of cholesterol esters 
(Kinney et al. 1994), 24-hydroxycholesterol, and 7-dehydrodesmosterol (Bourre 
et al. 1990) is observed, even before the time of myelination in the human CNS. 
It is therefore likely that neurons may be another important cell type that can 
synthesize cholesterol in the brain. This is supported by the finding in cultured rat 
sympathetic neurons that the cell bodies of neurons have the ability to synthesize 
cholesterol. This study also suggests that cholesterol synthesized by neuron cell 
bodies is sufficient for the elongation of axons (Vance et al.1994). 
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 As mentioned earlier, essentially all of the cholesterol in the brain is 
derived from local synthesis (Dietschy and Turley 2001). Cholesterol in 
membranes is held in place primarily with van der Waal's and hydrophobic forces. 
Cholesterol molecules can easily leave the bilayer membrane and then return. 
This type of turnover is rapid, but not easily detected. Metabolic turnover is very 
slow. Brain cholesterol is characterized by a low turnover and little exchange with 
lipoproteins in the circulation because of the protection of blood-brain barrier 
(Björkhem et al. 1997). Thus, mechanisms that remove cholesterol from the brain 
are required for the brain cholesterol homeostasis. Recent evidence suggests 
that a 24S-hydroxylase mediated mechanism could be the most important 
mechanism in the elimination of cholesterol in the brain (Björkhem et al. 1999). 
80% of the 24S-hydroxycholesterol in the human body is present in the brain, 
and the concentration of 24S-hydroxycholesterol is 30-1500 times higher in the 
brain than in any other organs except adrenals (Lütjohann et al. 1996).  
 A net flux has been demonstrated from the brain into the circulation by 
measuring the 24S-hydroxycholesterol in the serum samples from the internal 
jugular vein and the branchial artery in human (Lütjohann et al. 1996). Moreover, 
the rate of excretion of this compound into the plasma roughly equals the rate of 
cholesterol synthesis in the adult rat brain (Björkhem et al. 1997). Once the 24S-
hydroxycholesterol is synthesized, it is readily secreted across the blood-brain 
barrier into the circulation (Björkhem et al. 1997) and rapidly taken up and 
metabolized in the liver (Björkhem et al. 1998).  
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 24S-hydroxylase cDNA has been cloned and the expression of the 
enzyme in the mouse brain was studied by in situ hybridization and 
immunohistochemistry (Lund et al. 1999). 24S-hydroxylase is expressed in 
neurons rather than the cholesterol-laden cells or lipid-rich myelin sheaths. It is 
expressed in multiple subregions of mouse brain, including the cerebral cortex, 
hippocampus, dentate gyrus, and thalamus. These results suggest that the 24S-
hydroxylase mediated pathway is an important mechanism for elimination of 
cholesterol from the human brain (Lund et al. 1999).  
 
2. 2. 2. 2. Cholesterol binding/ transport proteins in the brain 
 Cholesterol transport and the proteins involved in such transport have 
been extensively studied in vitro and in systems outside the brain. In contrast, 
studies on cholesterol transport in the brain are relatively few. Most of the 
transport proteins found in brain tissues belong to either intracellular transport 
proteins or apolipoproteins. At least four families of transport proteins that may 
be involved in cholesterol trafficking have been reported in the brain. 
 The first group of intracellular cholesterol transport proteins found in the 
brain is SCP-2 (van Amerongen et al. 1985; Myers-Payne et al. 1996a). Pro-
SCP-2 was detected in brain by immunoblotting (Van Heusden et al. 1990) and 
was present in pinched off nerve ending or synaptosomes (Myers-Payne et al. 
1996a). An in vitro binding study reveals that SCP-2 can bind cholesterol with 
high affinity and it markedly facilitates transfer of cholesterol as well as other 
molecules, such as oxysterols and phospholipids (Schroeder et al. 1996). 
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Overexpressing the SCP-2 gene products led to upregulation of many aspects of 
cholesterol metabolism, including cholesterol uptake (Moncecchi et al. 1996), 
cellular cholesterol mass, cholesterol esterification (Murphy and Schroeder 1997), 
cellular cholesteryl ester mass, transfer of plasma membrane cholesterol to ER, 
and mitochondrial cholesterol oxidation (Yamamoto et al. 1991). However, thus 
far, the function role of SCP-2 in the brain has not been determined. Evidence 
shows that cholesterol is synthesized only in the cell body and transported to the 
axon by some unidentified mechanism in cultured sympathetic neurons (Vance et 
al. 1994). The isolation of SCP-2 from neurons suggests that it may be part of 
such a transport mechanism. 
 The second group of intracellular cholesterol transport proteins found in 
the brain is caveolin (Cameron et al. 1997; Ikezu et al. 1998). Caveolins belongs 
to a multimember family and caveolin 1, 2, 3 have been identified in brain 
endothelial cells and astrocytes (Cameron et al. 1997; Ikezu et al. 1998). Their 
functions are thought to be involved in the transport of cholesterol from ER to the 
plasma membrane (Smart et al.1996). 
 The third group of intracellular cholesterol transport proteins isolated from 
the brain is the fatty acid binding family. Two members of the family, H-FABP and 
B-FABP, are found in synaptosomes (Myers-Payne et al. 1996b). Interestingly, 
these proteins inhibit intermembrane sterol transfer in vitro instead of binding 
cholesterol (Pu et al. 1998). 
 The last group of cholesterol transport proteins reported in the brain is 
apolipoproteins. This family includes apolipoprotein A-I (apoA-I) (Harr et al. 1996), 
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apolipoprotein A-IV (apoA-IV), apolipoprotein E (apoE) (Pitas et al. 1987; Harr et 
al. 1996), apolipoprotein J (apoJ) (Harr et al. 1996), and apolipoprotein D (apoD) 
(Suresh et al. 1998). These apolipoproteins, which are the primary means of 
cholesterol trafficking systemically, are believed to be capable to bind cholesterol, 
esterified cholesterol, phospholipids, and triglycerides (Harr et al. 1996).  
 Among all the apolipoproteins found in the brain, apoE has been intensely 
studied as a result of the association between the apoE4 allele and AD (Poirier et 
al. 1993; Strittmatter et al. 1993; 1996). This apolipoprotein is thought to be 
synthesized in astrocytes and released to deliver cholesterol to other cells in the 
brain (Pitas et al. 1987). The released apoE enriched lipoproteins can bind to 
cells expressing the low-density lipoprotein receptor (LDL-R), VLDL receptor 
(VLDL-R), the low density lipoprotein receptor-related protein (LRP), and the 
apoE receptor 2 (apoER2). These receptors were observed in astrocytes, pial 
cells (Pitas et al. 1987; Wolf et al. 1992) and neurons (Poirier et al. 1993; Wolf et 
al. 1992; Christie et al. 1996; Narita et al. 1997). Besides apoE, there is 
increasing attention on the role of an atypical apolipoprotein, apoD, in the brain. 
 
2. 2. 2. 3. Apolipoprotein D 
 Apolipoprotein D (apoD), a member of the lipocalin superfamily of ligand 
transporters, has also been shown to localize in the brain (Peitsch and Boguski 
1990). ApoD was first isolated and partially characterized from plasma high 
density lipoproteins (HDL) in 1973 (McConathy and Alaupovic 1973). Human 
apoD cDNA was cloned and sequenced, and immunoreactive apoD was 
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expressed by cultured cells transfected with the clone cDNA (Drayna et al. 1986). 
Translation of the apoD gene sequence predicts a 169-amino acid mature protein 
preceded by a 20-residue hydrophobic leader peptide (Drayna et al. 1987). As a 
member of lipocalin protein family, apoD has three characteristic conserved 
sequence motifs, the kernel lipocalins. Unlike typical apolipoproteins, which 
feature an amphipathic α-helical structure that mediates noncovalent interaction 
with lipids, the tertiary structure of apoD is characterized by eight antiparallel β-
sheets (Peitsch and Boguski 1990), which form a ligand-binding pocket. The 
functional role of apoD is thought to be a transporter for several small 
hydrophobic molecules including cholesterol (Drayna et al. 1986), progesterone 
(Lea 1988; Balbin et al. 1990), porphyrins (Peitsch and Boguski 1990), and 
arachidonic acid (Morais et al. 1995).  
 ApoD showed high binding affinity to cholesterol (Patel et al. 1997). This is 
thought to have a physiological role in cholesterol transport. Such binding could 
allow translocation of cholesterol between domains of high and low 
concentrations of the sterols that are known to exist within cellular membranes 
(Patel et al. 1997). ApoD could also form a complex with lecithin cholesterol 
acyltransferase (LCAT). An increase in the cholesteryl esterification activity of 
LCAT is observed in presence of apoD and the formation of an apoD–LCAT 
complex appears to have a stabilizing effect on LCAT (Kostner and Steyer 1988). 
Thus, by increasing cholesterol esterification by LCAT, apoD could indirectly 
promote reverse cholesterol transport (Drayna et al. 1986). ApoD metabolism 
has been shown to interact with that of cholesterol. In mouse astrocytes, apoD 
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expression is induced by 25-hydroxycholesterol and apoD is secreted associated 
with lipids (Ong et al. 1997). 
 Arachidonic acid is a potential physiological ligand with highest affinity for 
apoD (Morais-Cabral et al. 1995).  ApoD could be implicated in the transport of 
arachidonic acid and play an important role in cellular regulation. Through its 
association with LCAT, apoD could also modulate the metabolism of arachidonic 
acid in lipoproteins by controlling the conversion of arachidonic acid (active form) 
into cholesteryl esters (inactive form) (Morais-Cabral et al. 1995). 
 The apoD gene is expressed in many tissues, with high levels of 
expression in spleen, testes and brain (Drayna et al. 1986). In a study on the 
cellular localization of apoD mRNA in the rhesus monkey brain by in situ 
hybridization (Smith et al. 1990), strong hybridization was observed in a number 
of cells within the subarachnoid space, as well as in a population of perivascular 
cells surrounding small vessels penetrating from the surface of the brain. Similar 
results have been observed in human brain by immunocytochemistry (Navarro et 
al. 1998). ApoD immunoreactivity is found in neuroglial cells, pial cells and 
perivascular cells, in the white matter (Boyles et al. 1990a; Smith et al. 1990; 
Patel et al. 1995; Navarro et al. 1998). ApoD is secreted in the CNS by 
oligodendrocytes and astrocytes, and has been postulated to participate in 
reinnervation of damaged neurons (Patel et al. 1995; Boyles et al. 1990b). 
 ApoD may participate in CNS maintenance and repair. Elevated apoD 
expression is present after experimental brain injury (Ong et al. 1997; Montpied 
et al. 1999, Franz et al. 1999; Terrisse et al. 1999), and in neurological disorders 
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such as AD (Terrisse et al. 1998; Thomas et al. 2003), NPC disease (Suresh et 
al. 1998), and prion disease (Dandoy-Dron et al. 1998). Increased apoD 
expression could be linked to the ability of apoD to function as a transporter of 
sterols, steroids, arachidonic acid or a still unidentified ligand in the brain that is 
implicated in tissue repair following injury (Rassart et al. 1998).  
 
2. 2. 3. Cholesterol in neurological disorders 
 There is considerable turnover of cholesterol in neurons and glia during 
brain growth, neuronal repair and remodeling (Dietschy and Turley 2001). 
Abnormalities in cholesterol metabolism have also been reported to play a role in 
the pathophysiology of AD (Eckert et al. 2000). The evidence for such an 
association is the epidemiological data indicating a relationship between the 
apoE4 allele and the occurrence of AD (Strittmatter and Roses 1996; Sparks 
1997). Production of Aβ appears to play a central role in the pathophysiology of 
AD. The β-secretase pathway is critical to the amyloid hypothesis because it 
generates Aβ. APP is first cleaved by β-secretase and then by the γ-secretase 
complex to yield Aβ. A critical reason that Aβ production is sensitive to 
cholesterol levels is because the activity of β- and γ-secretase complexes is 
dependent on cholesterol metabolism. Both β- and γ-secretase complexes reside 
in cholesterol-rich membrane domains within the membrane. β-Secretase 
appears to be particularly sensitive to membrane cholesterol content and is 
located in lipid rafts. Reducing cellular cholesterol appears to inhibit β-secretase 
activity (Cordy et al. 2003; Fassbender et al. 2001). γ-Secretase is an aspartyl 
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protease complex composed of the four core components APH-1, nicastrin 
(NCT), presenilin (PS), and PEN-2 (Capell et al. 2005), and also resides in 
cholesterol-rich membrane domains and the cleavage has also been shown to be 
affected by cholesterol content (Wahrle et al. 2002). 
 Cholesterol content is slightly but significantly increased in frontal cortex 
gray matter of AD patients with the apoE4 allele (Sparks 1997). However, 
another study concluded that brain cholesterol content may be lower in AD 
patients than that in non-demented subjects. The cholesterol to phospholipid 
ratio is decreased by 30% in the temporal gyrus, but not in the cerebellum, of the 
autopsied brains from AD patients compared to control brains (Mason et al. 
1992). The reduction in the cholesterol to phospholipid ratio is likely attributed to 
a reduction of cholesterol content since the phospholipid to protein ratio is similar 
in brains from AD patients and control subjects. Platelet membrane of AD 
patients has been found to be more fluid than control membranes and this 
difference in fluidity may be resulted from a reduction in membrane cholesterol of 
AD patients (Zubenko et al. 1987). 
 Several studies have indicated that the amount of 24-hydroxycholesterol is 
higher in plasma and cerebrospinal fluid of AD patients than in unaffected 
individuals (Lütjohann et al. 2000; Papassotiropoulos et al. 2002; Schonknecht et 
al. 2002), suggesting that the turnover of cholesterol in the brain is increased 
during the neurodegenerative changes of AD. In contrast, in other studies the 
amount of 24-hydroxycholesterol in plasma was found to be lower in advanced 
AD patients, and also in a murine model of AD, than in controls (Bretillon et al. 
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2000; Heverin et al. 2004). It is possible that an increased plasma level of 24-
hydroxycholesterol reflects ongoing neurodegeneration and/or demyelination, 
whereas a decrease in the amount of plasma 24-hydroxycholesterol reflects a 
selective loss of the population of neurons that express cholesterol 24-
hydroxylase (Björkhem and Meaney 2004). Thus, a reduction in cholesterol 
levels in the brains of AD patients might be the result, rather than the cause, of 
the enhanced neurodegeneration. 
 
2. 3. Ceramide 
2. 3. 1. Structure and functions 
 Besides phospholipids and cholesterol, another major group of lipids, 
sphingolipids, have long been regarded as structural and inert components of cell 
membranes. Sphingolipids comprise around 3% of the cell membrane. They are 
derivatives of long-chain bases and display a great structural diversity and 
complexity (Hakomori 1981).  
 A key sphingolipid is ceramide. The latter is comprised of a sphingosine 
backbone and fatty acid joined in an amide bond. The sphingosine base in 
ceramides is typically D-erythro-1, 3-dihydroxy-2-amino-14-octadecene (C18:1). 
Minor additional forms include C20:1 (mainly in brain), 1,3,4-trihydroxy-2-amino-
hexadecanol (phytosphingosine) and D-erythro-1,3-dihydroxy-2-amino-4,14-
octadecadiene. The fatty acid chain length of ceramide can vary from 2 to 28 
carbons, although C16 to C24 ceramides are most abundant in mammalian cells. 
These fatty acids are usually saturated or monounsaturated, and sometimes may 
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contain a hydroxyl group at the C2 position (α-hydroxy fatty acid) or on the 
terminal C atom (Cremesti et al. 2002). All sphingolipids contain ceramide as the 
basic hydrophilic component. They derive from ceramide through biosynthetic 
pathways that modify primarily the 1-hydroxyl position of the ceramide backbone 
(Spiegel and Merrill 1996). This hydroxyl group can serve as an acceptor for 
glucose in the first step of glycosphingolipid synthesis or as a phosphocholine 
acceptor to yield sphingomyelin. Conversely, in catabolic pathways, ceramide is 
most commonly cleaved at the amide bond to yield sphingosine and a fatty acid 
(Perry and Hannun 1998). 
 Ceramide is known to function within the cell membrane in both 
microdomain coalescence and receptor clustering (Bollinger et al. 2005), and is 
involved in many cellular events including apoptosis, growth arrest, differentiation, 
senescence, mediating an immune response, oxidative stress responses, and 
nitric oxide signaling (Kolesnick and Hannun 1999; Hannun and Obeid 2002; 
Pettus et al. 2002).  
 Several targets for ceramide action have been identified. They include 
kinases, phosphatases, proteases and various transcription factors including AP1, 
NF-κB, and IL-6 (Kolesnick and Kronke 1998; Ohanian and Ohanian 2001). 
Ceramide also interacts with cholesterol to form microdomains (caveolae) and 
lipid rafts (Simons and Toomre 2000; van Meer and Lisman 2002). These 
microdomains and lipid rafts have been implicated in the modulation of signal 
transduction, cell adhesion, and function of ion channels (Bock et al. 2003).  
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 Ceramide can interact with phospholipids to alter the physicochemical 
properties of neural membranes (Farooqui et al. 2004). These interactions are 
important because they constitute the physicochemical basis of several 
processes of potential physiological significance, namely the ceramide-
dependent increase in membrane permeability, transbilayer lipid motion, and 
lateral segregation of ceramide-enriched domains (Montes et al. 2002; Carrer 
and Maggio 1999; Ruiz-Arguello et al. 1998). In the brain, other important effects 
of ceramide in hippocampal neurons include modulation of ion currents, 
neurotransmitter release and synaptic transmission (Furukawa and Mattson 1998; 
Yang 2000).  
 
2. 3. 2. Ceramide generation and metabolism 
 Ceramide can be generated in cells by de novo synthesis or 
sphingomyelin hydrolysis. De novo synthesis of ceramide occurs in cytosolic face 
of the ER (Mandon et al. 1992) and in mitochondria (Bionda et al. 2004; Shimeno 
et al. 1998) and begins with the condensation of serine and palmitoyl-CoA to 
form 3-ketosphinganine as catalyzed by serine palmitoyltransferase (SPT). SPT 
is the first and rate-limiting enzyme in the pathway (Merrill et al. 1989; Merrill and 
Wang 1986; Perry et al. 2000). 3-Ketosphinganine is then reduced to form 
sphinganine, which is acylated to generate dihydroceramide. The acylation of 
sphinganine to form dihydroceramide is catalyzed by ceramide synthase. A trans 
double bond is then introduced at the 4–5 position to generate ceramide. 
Alternately, this pathway may reutilize sphingosine released by sequential 
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degradation of more complex sphingolipids for ceramide synthesis. Recent 
evidence suggests that exogenous, cell-penetrant, short chain ceramides recycle 
into long chain ceramides via this pathway (Ogretmen et al. 2002).  
 SPT consists of heterodimers of 53-kDa regulatory SPT1 and catalytic 63-
kDa SPT2 subunits and binds to the ER (Hanada et al. 1997; Hanada 2003). 
Ceramide synthase can utilize both sphingosine and sphinganine as substrates, 
and thus, ceramide can be directly generated from sphingosine and a fatty acyl-
CoA. Ceramide synthase has been localized to the ER (Michel and van Echten-
Deckert 1997), mitochondrial outer and inner membranes (Bionda et al. 2004). 
The enzymes involved in the de novo synthesis of cellular ceramide are 
principally localized within the ER and mitochondria. However, ceramide 
generated within a specific site may be subsequently transported to other cellular    
compartments (van Meer and Lisman 2002).  
 De novo synthesis of ceramide is an important pathway for increasing   
ceramide levels in response to tumor necrosis factor (TNF), chemotherapeutic 
agents, and ionizing radiation, resulting in apoptosis as reflected by nuclear 
morphology and DNA fragmentation (Perry and Hannun 1998). De novo 
production of ceramide is implicated in cell cycle arrest (Lee et al. 1998) and 
apoptosis (Kolesnick and Kronke 1998; Kroesen et al. 2001; Perry et al. 2000; 
Perry 2002).  
 Recent findings have highlighted the importance of the de novo synthetic 
pathway. Reduction of ceramide synthesis by inhibitors of SPT or ceramide 
synthase attenuates cell death (Edsall et al. 2001; Bieberich et al. 2001; 
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Korkotian et al. 1999). The disorder known as hereditary sensory neuropathy 
(HSN) was traced to certain missense mutations in SPT, resulting in increased 
activity. Subsequent increases in ceramide biosynthesis were proposed to trigger 
apoptosis in peripheral sensory neurons resulting in the progressive 
degeneration of dorsal root ganglia and motor neurons in these patients 
(Dawkins et al. 2001). 
 Besides de novo synthesis, ceramides can also be generated from the 
sphingomyelin pathway via the sphingomyelin hydrolysis catalyzed by distinct 
sphingomyelinases (SMase) (Kolesnick and Kronke 1998; Liu et al. 1997). 
SMases are classified by their pH optima, dependence on cofactors, such as 
magnesium and zinc, and subcellular location (Okazaki et al. 1989; 1990; 
Marchesini and Hannun 2004; Levade and Jaffrezou 1999; Samet and Barenholz 
1999; Stoffel 1999). Membrane neutral magnesium-dependent SMase (nSMase) 
and acid SMase (aSMase) are rapidly activated by diverse stress stimuli such as 
cytokines, antibody receptors steroids, G protein-coupled receptors and cellular 
stress, resulting in increased ceramide levels over a period of minutes to hours 
(Hannun et al. 2001; Mathias et al. 1998).  
 Once generated, ceramide can accumulate in the cell or may be 
converted into a variety of metabolites (Fig. 3). Phosphorylation by ceramide 
kinase (Hannun et al. 2001; Mathias et al. 1998) generates ceramide 1-
phosphate, while deacylation by either neutral or acid ceramidase (Li et al. 2002) 
yields sphingosine, which may then be phosphorylated by sphingosine kinases 
(SKs) to generate S1P. Ceramide can be glycosylated to form complex 
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glycosphingolipids in the Golgi apparatus or can be used to form sphingomyelin 




Figure 3. Major synthetic and metabolic pathways for ceramides (Kolesnick 2002) 
 
2. 3. 3. Ceramide in the brain 
 Both de novo and the sphinomyelin breakdown pathway have been shown 
involved in neuronal ceramide generation. De novo ceramide synthesis is 
involved in regulating various aspects of neuronal development and death. 
Studies using inhibitors of de novo ceramide synthesis (Wang et al. 1991), 
originally suggested an important role for de novo synthesis of ceramide in 
axonal and dendritic development of hippocampal neurons (Harel and Futerman 
1993; Schwarz and Futerman 1998). Similar results were also shown in Purkinje 
cells (Furuya et al. 1995). Treatment of sensory neurons with the ceramide 
synthesis inhibitors also inhibits the generation of ceramide and apoptosis 
induced by suramin (Gill and Windebank 2000).  
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 In neurons, distal axons are rich in nSMase activity but contain almost no 
aSMase activity, which is concentrated in cell bodies/proximal axons (de Chaves 
et al. 2000). Consequently, the axonal pool of ceramide responsible for the 
inhibition of axonal growth in sympathetic neurons is mostly generated by 
nSMase. NSMase is found at highest levels in brain, and its expression and 
specific activity rapidly increases in parallel with neuronal maturation during the 
neonatal period in the rat brain (Spence and Burgess 1978). This suggests that 
ceramide generated from sphingomyelin by nSMase may contribute to normal 
neuronal survival, growth and maturation of the CNS. In Neuro2a cells, bioactive 
ceramide generated in response to retinoic acid (RA) treatment is derived from 
both de novo synthesis and the activity of nSMase (Riboni et al. 1995). 
 Exogenous ceramide may either protect or kill neurons, depending upon 
the concentration and experimental paradigm used (Weisner and Dawson 1996a, 
b; Furuya et al. 1998; Irie and Hirabayashi 1998). The effects of ceramide on 
hippocampal neuron survival and dendrite outgrowth depend on the 
developmental neuronal stage and the concentration of ceramide used. At 
concentrations below 5 µM exogenous ceramide either does not affect survival 
during the first day in culture (Schwarz and Futerman 1997) or increases cell 
viability (Mitoma et al. 1998). At concentrations over 5 µM exogenous ceramide 
given to immature hippocampal neurons causes apoptosis (Mitoma et al. 1998, 
Schwarz and Futerman 1997). In addition, ceramide concentrations lower than 1 
µM protect hippocampal neurons from several insults such as excitotoxicity, 
FeSO4 and Aβ (Goodman and Mattson 1996). In mature hippocampal neurons 
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(after 6–7 DIV) even low concentrations of ceramide cause cell death (Mitoma et 
al. 1998). C6-ceramide (<3 mM) increased cell survival and neurite outgrowth 
and protected against excitotoxic agents whereas C6-ceramide (>3 mM) induced 
cell death (Mitoma et al. 1998). 
 Ceramide-induced apoptosis of cortical neurons is accompanied by 
caspase 3 and caspase 9 activation (Willaime et al. 2000; Willaime-Morawek et 
al. 2003). With respect to neurite development and extension, treatment of 
cortical neurons with ceramide causes rapid neurite retraction and loss of 
dendritic MAP2 immunoreactivity (Willaime et al. 2000; Willaime-Morawek et al. 
2003). Treatment of cerebellar granule cells in culture with exogenous short-
chain ceramides causes apoptosis (Colombaioni and Garcia-Gil 2004; Centeno 
et al. 1998; Toman et al. 2002; Vaudry et al. 2003). Serum/K+ deprivation or 
exposure of granule cells to the anticancer agent etoposide leads to 
accumulation of endogenous ceramide and cerebellar granule cells death 
(Vaudry et al. 2003). In addition to the activation of apoptosis, C2-ceramide 
induces rapid and transient activation of cell migration and inhibits neurite 
outgrowth in immature cerebellar granule cells (Falluel-Morel et al. 2005).   
 
2. 3. 4. Ceramide in neurological disorders 
 In addition to the effects of cholesterol on AD, substantial depletions of 
plasmalogen and sulfatide as well as dramatic increases in ceramide are 
manifested at the earliest clinically recognizable stage of AD. Ceramide elevation 
in the brain is evident at an early stage in AD patients (Han et al. 2002; Cutler et 
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al. 2004b; Satoi et al. 2005). The increase of ceramide in AD may result from 
membrane-associated oxidative stress and might be accompanied by a decrease 
in sphingomyelin (Cutler et al. 2004b). Alteration of sphingolipid metabolism 
might be associated with the development of sporadic AD and ceramides have 
emerged as significant regulators of APP cleavage and Aβ production. Addition 
of C6- ceramide or nSMase increases Aß generation by regulating β-cleavage 
through β-site APP cleaving enzyme 1 (BACE1) stabilization but without affecting 
γ-cleavage of APP in cultured cells expressing APP (Puglielli et al. 2003).   
 Ceramide has also been identified as a possible second messenger in Aβ-
induced death. Treatment of cultured cells with Aβ (Jana et al. 2004; Lee et al. 
2004; Cutler et al. 2004b) or intracerebral administration of Aβ to rats (Alessenko 
et al. 2004) causes ceramide elevation. The apoptotic effects of Aβ are mimicked 
by exogenous short-chain ceramides (Jana and Pahan 2004; Liu et al. 1998). 
Aβ-induced activation of nSMase has been demonstrated in human primary 
neurons, oligodendrocytes and cerebral endothelial cells (Jana and Pahan 2004; 
Lee et al. 2004; Yang et al. 2004). The mechanisms by which Aβ causes 
nSMase activation and ceramide accumulation seem to be redox-sensitive and 
activation of NADPH oxidase and/or regulation of glutathione metabolism (Jana 
and Pahan 2004). Ceramide elevation is accompanied by an increase in the 
peroxidation product 4-HNE and is prevented by the antioxidant α-tocopherol 
(Cutler et al. 2004b). 
 Recent finding has shown that overproduction of ceramide may be 
involved in neuronal death in HIV-associated dementia patients (Haughey et al. 
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2004). Sphingolipid deregulation is more pronounced in HIV-associated dementia 
patients with an apoE4 genotype, who have worse prognoses (Cutler et al. 
2004a).  
 Elevated levels of ceramide have also been detected in the brain after 
cerebral ischemia (Herr et al. 1999; Kubota et al. 1996; Nakane et al. 2000; 
Takahashi et al. 2004; Ohtani et al. 2004) and status epilepticus (Mikati et al. 
2003). A previous study demonstrated that ceramide is released in vivo in the 
post-ischemic rat brain. Maximal generation of ceramide occurs during the early 
phase of reperfusion and is mediated by enhanced aSMase activity as found by 
the use of a neuroblastoma cell line in an in vitro model for ischemia/reperfusion 
(Herr et al. 1999). Exogeneous ceramide have been shown to reduce the infarct 
size in focal cerebral ischemia with an upregulation of Bcl-2 and a reduction of 
TUNEL-positive cells (Chen et al. 2001). 
 In addition, dopaminergic and other neurons in primary cultures derived 
from the mesencephalon, a primary region of neuronal degeneration in PD, 
undergo apoptosis through a ceramide-dependent mechanism that may be 
identical to the cytokine-stimulated signaling pathway in the immune system. The 
presence of a ceramide-dependent apoptotic system in mesencephalic 
dopaminergic neurons suggests that inappropriate activation of such a cell death 
mechanism may be a factor contributing to PD (Brugg et al. 1996). 
 
3. Kainate-induced excitotoxic neuronal injury 
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 Excitotoxicity refers to a process of neuronal death caused by excessive 
or prolonged activation of glutamate receptors (GluRs) by the excitatory amino 
acid neurotransmitter glutamate (Olney et al. 1971). GluRs are categorized into 
two classes, ionotropic and metabotropic receptors (reviewed in Ozawa et al. 
1998). Glutamate activates postsynaptic receptors, including the ionotropic 
receptors. Upon activation, these receptors open their associated ion channel to 
allow the influx of Ca2+ and Na+ ions. Although physiological elevations in 
intracellular Ca2+ are salient to normal cell functioning, the excessive influx of 
Ca2+ together with any Ca2+ release from intracellular compartments can 
overwhelm Ca2+-regulatory mechanisms and lead to cell death (Choi 1987). This 
phenomenon known as excitotoxicity contributes to neuronal degeneration in 
many acute CNS disorders, including ischemia, trauma, and epilepsy, and may 
also play a role in chronic neurodegenerative diseases (reviewed in Arundine 
and Tymianski 2003). 
 Kainic acid (KA) is a rigid analog of the excitatory amino acid glutamate 
that binds to and activates ionotropic glutamate receptor. Kainate-induced 
epileptic seizures have been widely used as a model for studying human 
temporal lobe epilepsy (Sloviter and Dempster 1985; Represa et al. 1990; Sutula 
et al. 1992). A single systemic injection of a convulsive dose of kainate results in 
both short- and long-term effects on the rat CNS. Within 1 h of its administration 
to the rats, the neuronal circuitry of the hippocampus is activated and later the 
animal undergoes robust and recurrent seizures. Within 3-4 days after kainate 
injection, pyramidal cells in CA1 and CA3 field of the hippocampus begin to 
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degenerate (Coyle et al. 1983; Sutula et al. 1992; Bing et al. 1996). 1-2 weeks 
later, spontaneous convulsions can be observed in kainate-treated rats. KA 
produces selective degeneration of neurons after intraventricular and 
intracerebral injection, especially in the striatal and hippocampal areas of the 
brain (Lerma 1997; Ben-Ari and Cossart 2000). Axons and nerve terminals are 
more resistant to the destructive effects of KA than the cell soma. In developing 
brains, however, administration of KA fails to produce neurotoxicity (Sperber et al. 
1991). Instead, low doses of KA appear to exert trophic effects such as increases 
in survival and neurite outgrowth in cultured neurons derived from the cerebellum, 
hippocampus, and spinal cord (Balazs and Hack 1990).  
 KA has been injected into the ventral globus pallidus of rats to produce 
neurodegeneration of cholinergic neurons in a pattern similar to nerve cell loss in 
AD (Johnston et al. 1979). Neurofibrillary tangles and neuritic plaques similar to 
those found in AD have been shown in cerebral cortical and hippocampal 
neurons after KA injection in rats (Arendash et al. 1987). In addition, KA 
injections into the rat striatum produce behavioral, biochemical and 
morphological effects similar to those described in human afflicted with 
Huntington's chorea (Coyle and Schwarcz, 1976; McGeer and McGeer 1976).  
 An increasing number of studies suggest a caused relation between 
excitotoxicity and free radicals in vivo (Bondy and Lebel 1993; Nakao and 
Brundin 1998). Increased concentration of malonaldehyde and 4-hydroxyalkenals, 
which was measured as an index of lipid peroxidation, was found in rat cerebral 
cortex, cerebellum, hippocampus, hypothalamus, and corpus striatum after 
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administration with KA (Melchiorri et al. 1995; Bruce and Baudry 1995). These 
results suggest the involvement of oxygen free radicals in the initial phases of 
KA-induced pathology. 
 KA can cause excitotoxic neuronal death through interacting with kainic 
acid-type receptors in neurons, which induces neuronal Ca2+ overloading. The 
alteration in Ca2+ homeostasis and its short duration may lead to neuronal 
degeneration by the activation of PLA2 and subsequent arachidonic acid cascade. 
Elevated levels of arachidonic acid and its metabolites produce a variety of 
detrimental effects on neural membrane structure, activities of membrane 
enzymes, and neurotransmitter uptake systems (Farooqui and Horrocks 1994; 
Farooqui et al. 1997). Thus, KA receptor-mediated degradation of neuronal 
membrane phospholipids, calcium overload, and oxidative stress can disrupt 
cellular homeostasis and thus threaten cellular membrane integrity and viability 
and lead to neurodegeneration (Farooqui et al. 2000b). 
 
4.  Aims of the present study 
 In contrast to kainate-induced dysregulated phospholipid metabolism, 
relatively little is known about altered cholesterol and ceramide metabolisms after 
kainate injury. In view of importante role of these two membrane lipids in the 
brain function, the present study aimed to elucidate changed concentrations of 
cholesterol, 24-hydroxycholesterol, 7-ketocholesterol, and ceramides after 
kainate injury. The altered expression and activity of a cholesterol metabolic 
enzyme, cholesterol 24-hydroxylase, and a ceramide synthetic enzyme, SPT, 
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after kainate injury were also carried out. Finally, the role of apoD in modulation 
of kainate-induced changed levels of cholesterol, cholesterol oxidative products, 
and an oxidative stress biomarker, F2-isoprostanes, and neurodegeneration were 
elucidated.  This study is composed of several parts as follows: 
   
4.1. Dysregulation of cholesterol metabolism after kainate injury 
 Kainate injection has been shown to result in increased immunoreactivity 
to cholesterol in the affected CA fields of the hippocampus (Ong et al. 2003). 
However, it is not known whether this increased cholesterol expression is 
associated with changes in the expression of the cholesterol metabolic enzymes 
and with the disturbance of cholesterol turnover in the kainate-induced 
excitotoxic brain. The effect of an inhibitor of cholesterol biosynthesis, lovastatin, 
on kainate-induced brain injury is still not clear.   
 The methods of western blot, immunohistochemistry, immunofluorescence 
and electron microscopy were carried out to investigate the expression change of 
cholesterol 24-hydroxylase, and any correlation with cholesterol levels in the rat 
hippocampus after kainate lesion. The method of GS/MS was carried out to 
quantify the concentration of cholesterol, 24-hydroxycholesterol and 7-
ketocholesterol in kainate or kainate plus lovastatin treated rat hippocampus and 
hippocampal slices. Cell survival was measured using MAP2 immunostaining 
and LDH assay. 
 
4. 2. Dysregulation of ceramide metabolism after kainate injury 
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Recent studies suggest that in addition to the alterations of cholesterol 
metabolism, an abnormality in ceramide metabolism is involved in 
neurodegenerative diseases such as AD and stroke. Although previous studies 
have demonstrated a role for sphingomyelinase activity in ceramide 
accumulation during neurodegeneration, relatively little is known about possible 
contributions from ceramide biosynthetic activity.  
 The methods of western bloting, immunohistochemistry, 
immunofluorescence, electron microscopy and SPT enzyme activity assay were 
used to elucidate the altered distribution and activity change of SPT, and any 
correlation with ceramide levels in the rat hippocampus after kainate lesion. The 
method of ESI-MS was carried out to quantify ceramide levels in the kainate or 
kainate plus SPT inhibitor treated hippocampal slices. Cell survival was 
measured using MAP2 immunostaining and LDH assay. 
 
4. 3. Effect of apolipoprotein D on the neuronal injury after kainate injury 
 ApoD has the ability to bind several small hydrophobic ligands, including 
arachidonic acid and cholesterol. A marked increase of apoD expression in the 
rat hippocampus after kainate-induced neuronal injury has been shown (Ong et 
al. 1997), and the increase in apoD is paralleled by decreases in phospholipid 
level and increases in arachidonic acid, ceramide and cholesterol levels in the 
kainate-injured hippocampus. One possibility is that apoD may be upregulated in 
injured neurons as part of a cellular defensive mechanism by regulating lipid 
metabolism. 
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 The method of GC/MS was carried out to quantify F2-isoprostane, 
cholesterol, 24-hydroxylcholsterol, and 7-ketocholesterol levels in kainate-treated 
hippocampal slices. The effect of oxidative stress on cultured fibroblasts from 
wild type and apoD knockout mice was also studied, as a comparison. Cell 















































I. Lovastatin modulates increased cholesterol and 
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 Oxysterols or cholesterol oxidation products are products of cholesterol 
metabolism, and play important roles in cholesterol turnover, atherosclerosis and 
inflammation (Björkhem and Diczfalusy 2002). Because of their ability to pass 
through cell membranes and the blood-brain barrier at a faster rate than 
cholesterol itself, they are also important as transport forms of cholesterol. 
Oxysterols can be formed by direct oxidation of cholesterol, or through the action 
of oxysterol biosynthetic enzymes (Russell 2000). 7β-Hydroxycholesterol and 7-
ketocholesterol are formed by the direct oxidation of cholesterol (Miguet-Alfonsi 
et al. 2002). In contrast, 24-hydroxycholesterol, 25-hydroxycholesterol and 27-
hydroxycholesterol are produced by enzymatic action. Increased levels of 7β-
hydroxycholesterol and 7-ketocholesterol are present in atherosclerotic plaques 
(Brown et al. 1997). These two oxysterols are also increased in patients with 
aceruloplasminemia (Miyajima et al. 2001). 
 The enzyme cholesterol 24-hydroxylase synthesizes 24-
hydroxycholesterol, and to a lesser extent, 25-hydroxycholesterol. This enzyme 
is expressed mainly in the brain, and is normally present in neurons (Lund et al. 
1999). The conversion of CNS cholesterol to 24-hydroxycholesterol, which 
readily crosses the blood brain barrier, is a major pathway for brain cholesterol 
efflux and maintenance of CNS cholesterol homeostasis (Björkhem et al. 1998; 
1999; Lund et al. 2003). Increased expression of cholesterol 24-hydroxylase has 
been reported in the brain in Alzheimer’s disease (Bogdanovic et al. 2001; Brown 
et al. 2004). Oxysterols including 7-ketocholesterol (Lizard et al. 2000; Ong et al. 
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2003) and 24-hydroxycholesterol (Kolsch et al. 1999; 2001) are toxic to cells in 
culture. 
 Intracerebroventricular injection of kainate, a model of excitotoxic injury, 
causes acute neuronal death of the affected CA subfields in the hippocampus, 
and proliferation and hypertrophy of glial cells in the glial scar (Farooqui et al. 
2001). Our previous study has shown that there is significant de novo synthesis 
of cholesterol in the degenerating hippocampus after neuronal injury (Ong et al. 
2003), and that the cholesterol is directly oxidized to oxysterols at relatively short 
time intervals (3 days) after kainate injury. The present study was carried out to 
determine whether there could be changes in oxysterol biosynthetic enzyme 
expression and oxysterol formation at longer time intervals after kainate 
injections. HMG-CoA is the rate-limiting enzyme for cholesterol synthesis in liver 
and other tissues (Brown and Goldstein 1980). We also examined whether 
treatment by a brain permeable 3-hydroxy 3-methylglutaryl coenzyme A (HMG-
CoA) reductase inhibitor, lovastatin, could affect brain cholesterol and oxysterol 
levels and neuronal survival after kainate injury. 
 
2. Materials and Methods 
2. 1. Animals and intracerebroventricular kainate injection 
 Wistar rats weighing approximately 200 g were anesthetized with an 
intraperitoneal injection of 1.2 ml of 7% chloral hydrate, and the cranial vault 
exposed. Kainate (1 µl of a 1 mg/ml solution) was injected into the right lateral 
ventricle (coordinates: 1.0 mm caudal to bregma, 1.5 mm lateral to the midline, 
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4.5 mm from the surface of the cortex) using a microliter syringe. The needle was 
withdrawn 10 min later, and the scalp sutured. Experimental control rats were 
injected with 1 µl of saline instead of kainate. All procedures involving animals 
were in accordance with guidelines of the Guide of National Research Council of 
Singapore for the care and use of laboratory animals, and approved by the 
Institutional Animal Care and Use Committee. 
 
2. 2. Western blots 
 This was carried out to demonstrate specificity of the cholesterol 24-
hydroxylase antibody. Two kainate-injected rats and two saline-injected rats were 
killed 2 weeks after injection. The rats were deeply anesthetized with an 
intraperitoneal injection of 7% chloral hydrate, and killed by decapitation. The 
right hippocampi from both animals in each treatment group were pooled, and 
homogenized in 10 volumes of ice-cold buffer containing 0.32 M sucrose, 4 mM 
Tris-Cl, pH 7.4, 1 mM EDTA, and 0.25 mM dithiothreitol (DTT). After 
centrifugation at 1000 xg for 15 min, the supernatant was collected, and protein 
concentrations in the preparation measured using the BioRad protein assay kit. 
Total proteins (50 µg) were resolved in 10% SDS-polyacrylamide gels under 
reducing conditions and electrotransferred to a polyvinylidene difluoride (PVDF) 
membrane (Amersham Pharmacia Biotech, Little Chalfont, UK). Nonspecific 
binding sites on the PVDF membrane were blocked by incubation with 5% non-
fat milk for 1 h. The PVDF membrane was then incubated overnight with a rabbit 
polyclonal antibody to cholesterol 24-hydroxylase (diluted to 2 µg/ml in Tris 
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buffered saline [TBS]). The antibody to cholesterol 24-hydroxylase was raised in 
the rabbit against amino acids 254-270 of the mouse cholesterol 24-hydroxylase, 
and has been shown to detect a single band at ~56 kDa in brain (Lund et al. 
1999). After washing with 0.1% Tween-20 in TBS, the membrane was incubated 
with horseradish peroxidase-conjugated goat anti-rabbit immunoglobulin IgG 
(Amersham) for 2 h at room temperature. The protein was visualized with an 
enhanced chemiluminescence kit (Pierce, Rockford, IL, USA) according to the 
manufacturer's instructions. 
 
2. 3. Immunohistochemical analyses 
2. 3. 1. Immunoperoxidase labeling 
 Four kainate-injected rats at each post-injection time interval were killed at 
1 day, 3 days, 1 week, 2 weeks and 4 weeks after injection. Four saline-injected 
rats at 2 weeks after injection were used as experimental controls. The rats were 
deeply anesthetized by intraperitoneal injection of 1.5 ml of 7% chloral hydrate 
and perfused through the left cardiac ventricle with a solution of 4% 
paraformaldehyde in 0.1 M phosphate buffer (pH 7.4). The brains were removed, 
and a block consisting of the posterior two thirds of the forebrain, including the 
hippocampi, dissected out. The blocks were sectioned coronally at 100 µm using 
a vibrating microtome. The sections were divided into four sets, for cresyl fast 
violet (Nissl), and immunohistochemical staining as follows: sections were 
washed for 3 h in phosphate buffered saline (PBS) to remove traces of fixative. 
They were then incubated overnight with a mouse monoclonal antibody to 
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cholesterol (MAb 2C5-6, 1:50 dilution), or a rabbit polyclonal antibody to 
cholesterol 24-hydroxylase (diluted to 10 µg/ml in PBS). MAb 2C5-6 has 
previously been characterized and shown to be specific for cholesterol (Swartz et 
al. 1998). The sections were washed in three changes of PBS, and incubated for 
1 h at room temperature in a 1:200 dilution of biotinylated horse anti-mouse IgG, 
or goat anti-rabbit IgG (Vector, Burlingame, CA, USA). The sections were then 
reacted for 1 h at room temperature with an avidin-biotinylated horseradish 
peroxidase complex, and the reaction visualized by treatment for 5 min in 0.05% 
3,3-diaminobenzidine tetrahydrochloride (DAB) solution in Tris buffer containing 
0.05% hydrogen peroxide. The color reaction was stopped with several washes 
of Tris buffer, followed by PBS. Some sections were mounted on glass slides and 
lightly counterstained with methyl green before cover slipping. The remaining 
sections were processed for electron microscopy. Control sections were 
incubated with cholesterol-absorbed antibody (prepared by incubating 5 µg/ml of 
cholesterol with 1:50 dilution of cholesterol antibody overnight), pre-immune 
rabbit serum, or PBS, instead of primary antibodies. They showed absence of 
staining. 
 
2. 3. 2. Quantitation of labeled cells in vivo 
The number of cholesterol positive neurons or cholesterol 24-hydroxylase 
positive glial cells in lesioned areas of dosal CA1 subregion of the right 
hippocampus of each rat was counted manually using a light microscope. The 
counts were conducted in a "blind" manner on coded slides at 200 x 
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magnification with the help of a grid. A total area of 200 x 300 µm from each 
section, and four sections from each of the four rats in each category were 
analyzed. The pyramidal neurons in CA fileds are dispersed and can be 
separated for counting with the help of microscope. The mean number of stained 
cells/ mm2 was then calculated for each group of rats at a specific time interval 
after kainate injection (n = 4 per group). The 'unlesioned' control group consisted 
of four rats at 2 weeks after saline injection.  
 
 2. 3. 3. Electron microscopy 
Electron microscopy was carried out by subdissecting some of  
immunostained sections into smaller portions that included the lesioned CA1 field. 
These were osmicated, dehydrated in an ascending series of ethanol and 
acetone, and embedded in Araldite. Thin sections were obtained from the first 5 
µm of the sections, mounted on copper grids coated with Formvar, and stained 
with lead citrate. They were viewed using a Jeol 1010EX electron microscope. 
 
2. 3. 4. Double immunofluorescence labeling 
Four kainate-injected rats and four saline-injected rats were killed at 2 
week post-injection. The rats were deeply anesthetized by intraperitoneal 
injection of 1.5 ml of 7% chloral hydrate, and transcardially perfused with normal 
saline, followed by a fixative, consisting of 4% paraformaldehyde in 0.1 M 
phosphate buffer (pH 7.4). The brains were dissected out and blocks containing 
the hippocampus sectioned coronally at 30 µm thickness using a freezing 
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microtome. They were washed for 3 h in phosphate buffered saline containing 
0.1% Triton-X 100 (PBS-Tx) to remove traces of fixative, and immersed for 1 h in 
a solution of 5% normal goat serum (Vector) in PBS-Tx to block non-specific 
binding of antibodies. The sections were then incubated overnight with a rabbit 
polyclonal antibody to cholesterol 24-hydroxylase (diluted to 10 µg/ml in PBS), 
and a mouse monoclonal antibody to GFAP (a marker for astrocytes, diluted to 1 
µg/ml in PBS, Chemicon, Temecula, CA, USA). This was followed by three 
washes of PBS and incubation for 1 h at room temperature in 1:200 dilution of 
fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse IgG, and Cy3-
conjugated goat anti-rabbit IgG (both from Chemicon). The sections were 
mounted and examined using an Olympus FluoView FV500 confocal microscopy. 
Control sections incubated with PBS instead of primary antibodies. They showed 
absence of staining. 
 
2. 4. Hippocampal slice cultures  
Hippocampal slice cultures were prepared as previously described 
(Stoppini et al. 1991) with minor modifications (Lu et al. 2001). In brief, 10 day old 
Wistar rat pups were anesthetized with intraperitoneal injections of 3.5% chloral 
hydrate, decapitated, and the brain removed. The hippocampi were dissected out, 
and sectioned transversely at 350 µm thickness using a tissue chopper. The 
slices were transferred to 30 mm Millicell CM culture plate inserts with 0.4 µm 
polytetrafluoroethylene membranes (Millipore, Bedford, MA, USA), and placed in 
6-well culture plates containing culture medium (50% minimum essential medium 
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[Gibco], 25% horse serum [Sigma, St Louis, MO, USA], 25% Hanks balanced 
salt solution [Gibco], supplemented with D-glucose [6.5 mg/ml, Sigma], glutamine 
[2 mM, Gibco], penicillin G [1 unit/ml, Gibco] and streptomycin sulfate [1 µg / ml, 
Gibco], pH 7.15). The slices were maintained at 37°C, 100% humidity, 95% air 
and 5% CO2. The medium was changed to fresh medium every 3 days in culture. 
The effects of kainate and other agents were tested in cultures after 14 days in 
vitro. 
 
2. 5. Gas chromatographic/mass spectrometric (GC/MS) analysis 
2. 5. 1. Kainate and lovastatin treatment 
Initial experiments were performed to elucidate the time course of 
cholesterol and oxysterol formation after kainate injection. Four kainate-injected 
rats were killed at 3 days, 1 week, 2 weeks and 4 weeks after injection. The 
animals were anaesthetized by intraperitoneal injections of chloral hydrate and 
decapitated. The lesioned right hippocampi were quickly removed, and snap 
frozen in liquid nitrogen, and kept in an -80°C freezer till analysis. Four 2 week 
post-saline-injected rats were used as experimental controls. 
Subsequent experiments were carried out to investigate possible effects of 
lovastatin on cholesterol and oxysterol levels after kainate treatment. For in vivo 
analyses, eleven kainate-injected rats were injected intracerebroventricularly with 
kainate and intraperitoneally with lovastatin (4 mg/kg) 3 h after the kainate 
injection, followed by daily injections of the same dose of lovastatin till the time of 
sacrifice at 1 week (6 rats) or 2 weeks (5 rats) after kainate injection. The rats 
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showed status epilepticus that peaked at 90 to 180 mins after kainate injection 
(Lothman and Collins 1981), and this had abated by the time of the first injection 
of lovastatin (3 hours after kainate injection). The lovastatin solution was 
prepared by dissolving pure lovastatin (kind gift of Ranbaxy Malaysia Sdn Bhd) in 
20% ethanol and diluted to the final concentration with saline (pH 7.4). Fresh 
solutions were used daily. Another nine kainate-injected rats were 
intraperitoneally injected with 20% ethanol in saline for 1 week (4 rats) or 2 
weeks (5 rats), and were used as controls. The right hippocampi of the above 
rats were removed for analysis. 
In vitro analysis of the effect of lovastatin was also carried out. Kainate 
(100 µM final concentration) was applied to slice cultures for 3 h in serum-free 
medium. The medium was removed, and the slices treated with fresh serum-free 
medium containing lovastatin or vehicle for 24 h. The above concentration of 
kainate has been shown to be toxic to neurons in hippocampal slice cultures (Lu 
et al. 2001). Lovastatin was prepared as a 25 mM stock solution in 100% ethanol 
and stored at 4°C. This was diluted to a 2.5 mM solution in sterile water and 
further diluted in serum-free medium to a final concentration of 1 µM. The vehicle 
consisted of similarly diluted ethanol. Material from twelve to sixteen slices in 
each treatment group was collected for a single experiment. The mean and 
standard deviation from three separate experiments were then calculated. 
All reagents for GC/MS analysis were of analytical grade. Standards for 
cholesterol, 7-ketocholesterol, 25-hydroxycholesterol, cholesterol 5 alpha, 6 
alpha-epoxide, cholesterol 5 beta, 6beta-epoxide, 5α-cholestane and ergosterol 
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were purchased from Sigma and of at least 95% purity. 24S-hydroxycholesterol 
(non-deuterated) was purchased from Medical Isotopes (Pelham, AL, USA). 5α-
cholestane and ergosterol were used as internal standards. Standard solutions of 
cholesterol, oxysterols, 5α-cholestane and ergosterol were diluted in ethanol. 
 
2. 5. 2.  Lipid extraction 
Extraction of lipids was carried out using Folch's method (Folch et al. 1957) 
with slight modification. Hippocampal specimens were homogenized at 4°C with 
1.5 ml PBS (pH 7.4) and 6 ml Folch organic solvent mixture 
(chloroform/methanol 2:1, containing 0.05% butylated hydroxytoluene [BHT]). 
The cultured hippocampal slices were homogenized at 4°C with 0.5 ml PBS (pH 
7.4) and 2 ml Folch organic solvent mixture. The homogenates were sealed 
under N2 and centrifuged at 1000 x g for 10 min at 4 °C. The upper phase was 
discarded and the lower organic phase carefully transferred to a glass vial and 
evaporated under a stream of N2.  
 
2. 5. 3. Lipid hydrolysis 
 2 ml of 0.5 M KOH (in 50% methanol) was added with 400 ng ergosterol 
and 10 µg 5α-cholestane, and the vial sealed under N2. The lipid extract was 
hydrolyzed at 23°C for 2 h in the dark. 
 
2. 5. 4. Cholesterol and oxysterol extraction 
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2.7 ml formic acid (40 mM), 0.2 ml HCI (5 M) and 0.5 ml methanol were 
added in the above dydrolysed lipid extract and thoroughly mixed before loading 
onto a 3 ml, 60 mg Oasis Mixed Anion Exchange (MAX) solid phase extraction 
column (Waters, Milford, MA, USA) previously conditioned with 2 ml methanol 
and 2 ml formic acid (20 mM). The column was then washed with 2 ml 2% 
ammonium hydroxide followed by 2 ml methanol/formic acid (40/60). Cholesterol 
and oxysterols were eluted with 2 ml hexane followed by 2 ml ethyl 
acetate/hexane (30/70), and collected together into a glass tube containing 50 
mg Isolute HM-N (International Sorbent Technologies) to remove traces of water. 
50 µl of the extract was aliquoted into a separate glass vial and evaporated under 
N2 for cholesterol analysis, and the remaining organic solvent was evaporated 
under N2 for oxysterols analysis. Aliquots for cholesterol analysis were 
derivatized with 25 µl acetonitrile and 25 µl N,O-
bis(trimethylsilyl)trifluoroacetamide (BSTFA) + 1% trimethylchlorosilane (TMCS) 
for 1 h at room temperature and injected directly onto GC/MS. Samples for 
oxysterol analysis were derivatized with 50 µl acetonitrile and 50 µl BSTFA + 1% 
TMCS for 1 h at room temperature, evaporated to dryness under N2 and 
reconstituted in 30 µl undecane before injection into the GC/MS. 
 
2. 5. 5. GC/MS measurement 
 Cholesterol and oxysterols were both analyzed with a Hewlett-Packard 
5973 mass selective detector interfaced with a Hewlett-Packard 5890II gas 
chromatograph and equipped with an automatic sampler and a computer 
 51
workstation. Separations were carried out on a fused silica capillary column (12 
m x 0.2 mm i.d.) coated with cross-linked 5% phenylmethylsiloxane (film 
thickness 0.33 µm) (Ultra2, Agilent). The carrier gas was helium with a flow rate 
of 1 ml/min (average velocity = 55 cm/sec). Selected-ion monitoring was 
performed using the EI mode at 70 eV with the ion source maintained at 230°C 
and the quadrapole at 150°C. One target ion and two qualifier ions selected from 
each compound mass spectrum were monitored to optimize sensitivity and 
specificity. Quantitation of modified bases was achieved by relating the peak 
area of the analyte with its corresponding internal standard.  
 
2. 5. 6. Cholesterol analysis 
Derivatized samples (1 µl) were injected with a 25:1 split into the GC 
injection port (280°C). Column temperature was increased from 240°C to 300°C 
at 25°C/min after 1 min at 240°C, and then held at 300°C for 4 min. Cholesterol 
was monitored using m/z 329 as target ion and m/z 458, 453 as qualifier ions and 
5α-cholestane was monitored as internal standard (target ion = m/z 357, qualifier 
ions = m/z 372, 232). 
 
2. 5. 7.  Oxysterol analysis 
Derivatized samples (1 µl) were injected with a 5:1 split into the GC 
injection port (280°C). The column temperature was increased from 175°C to 
280°C at 30°C/min after 1 min at 175°C, then increased to 291°C at 2°C /min. 
Finally, the oven temperature was increased to 306°C at 30°C /min and held for 
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1.5 min. Ergosterol was monitored as internal standard for the quantification of 
oxysterols. Target ions for 24-hydroxycholesterol and 7-ketocholesterol were m/z 
413 and m/z 472 respectively. Quantification of cholesterol and oxysterols was 
achieved by relating the peak area of the compound with the internal standard 
peak area and by applying the following formula: ng/mg hippocampus = (A/AIS) x 
[IS] x (1/k) ÷ hippocampus weight, where A = peak area of product, AIS = peak 
area of the internal standard, [IS] = concentration of the internal standard (400 ng 
ergosterol or 10 µg 5α-cholestane), k = relative molar response factor for each 
product calculated from the gradient of the calibration curve for each product. 
Data were expressed as mean ± standard deviation. Calibration curves were 
constructed from 5 different concentrations in triplicate of cholesterol (5 to 2500 
µg) as well as oxysterols (5-2500 ng), and showed good linearity (r2 > 0.95).  
 
2. 6. In vivo effect of lovastatin on neuronal survival after kainate injury 
A further ten male Wistar rats (each weighing approximately 200 g) were 
injected with kainate as described above. The injected rats were randomly 
divided into two groups (5 rats each). The first group received an 
intracerebroventricular injection of kainate as described previously, followed 3 h 
later by an intraperitoneal injection of lovastatin (4 mg/kg dissolved in vehicle 
consisting of 20% ethanol diluted in saline), following by daily injections of the 
same dose of lovastatin till the time of sacrifice at 2 weeks after kainate injection. 
The second group of rats was used as controls. These received 
intracerebroventricular injection of kainate followed by intraperitoneal injections of 
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vehicle, following the same schedule as the lovastatin-treated rats. The rats were 
killed at 2 week post-kainate injection by transcardial perfusion. Blocks 
containing the hippocampus were sectioned as described above. The sections 
were stained using the Nissl technique, or immunostained for microtubule 
associated protein 2 (MAP2, Sigma, diluted 1:500) to demonstrate viable 
neurons. The slides were coded and quantitation was carried out in a “blinded” 
manner. Due to the patchy nature of the cell loss even within a CA fields (i.e CA1 
and CA3), and the enormous total number of cells in entire hippocampus, direct 
counting of cells was not carried out. Instead the portion of surviving neurons in 
CA fields was estimated by taking digital images of the entire right hippocampus 
from 6 Nissl or MAP2 stained sections from each rat, and a discontinous line 
traced along the row of hippocampal pyramidal neuronal cell bodies from 
hippocampal fields CA1 to CA3. This was followed by a second trace, along the 
viable pyramidal neurons in the Nissl stained sections, or pyramidal neurons that 
showed immunolabeling in their cell bodies and dendrites in the MAP2 labeled 
sections. The ratio of the second to the first trace was calculated, to indicate the 
percentage of uninjured neurons in the CA fields.  
 
2. 7. In vitro effect of lovastatin on neuronal survival after kainate injury 
Kainate (100 µM) was applied to slice cultures for 3 h in the serum-free 
media before treatment of lovastatin (1 µM) or vehicle 24 h in fresh serum-free 
media. Slices (6 slices per group) were fixed by immersion in 4% 
paraformaldehyde in 0.1 M phosphate buffer (pH 7.4), after treatment. The 
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polytetrafluoroethylene membranes were cut from the culture plate inserts, 
washed, and immunostained with the attached slices for MAP2. The number of 
labeled neurons was counted as described in Chapter II, I. 2. 3. 2 (page 44).  
 Cellular injury in the hippocampal slices was also estimated by 
quantitation of lactate dehydrogenase (LDH) released from the slices into the 
culture media. LDH present in the culture supernatant (due to plasma membrane 
damage) participates in a coupled reaction which converts a yellow tetrazolium 
salt into a red, formazan-class dye which is measured by absorbance at 492 nm 
(Decker and Lohmann-Matthes 1988). The culture media were collected after 
various treatments, and analysed using a LDH cytotoxicity detection kit (Roche, 
Mannheim, Germany) as follows: neuronal death = [(A-Min)/(Max- Min)]x100, in 
which A is LDH activity measured in media of test condition, Max is maximum 
LDH release after 3 h treatment with Triton X-100, defined as 100% of cell death, 
Min is the LDH activity in media of untreated slices. Media from three culture 
dishes in each treatment group was collected for a single experiment. The mean 
and standard deviation from three separate experiments were then calculated. 
 
2. 8. In vitro effect of oxysterols on neuronal survival  
The toxicity of 24-hydroxycholesterol (15 µM and 50 µM of final 
concentration) on cultured hippocampall slices was determined by MAP2 staining 
and LDH release as described above. Oxysterols were dissolved in 100% 
ethanol at a concentration of 5 mM, and stored at -20°C before use. They were 
added to slice cultures for 24 h in serum-free medium. Control slices were 
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treated with vehicle (ethanol). The latter had no effect on cell viability at the 
concentration used (Wang et al. 2002). 
 
2. 9. Statistical analysis 
 Experimental data were subjected to statistical analysis using Student's t-
test or 1-way ANOVA with Bonferroni's multiple comparison post-hoc test (SPSS 
for Windows software). P < 0.05 was considered significant.  
 
3. Results 
3. 1. Western blot analysis (Fig. 1. 1) 
The antibody to cholesterol 24-hydroxylase detected a single band at ~56 
kDa in both the saline and kainate-injected rat hippocampus (Fig. 1. 1). This is 
consistent with the expected molecular weight of the enzyme, and similar to 
results obtained from the mouse brain (Lund et al. 1999; 2003). 
 
3. 2. Immunohistochemical analyses of cholesterol 24-hydroxylase after 
kainate lesions (Fig. 1. 2 and 1. 3; Table 1. 1) 
3. 2. 1. Light microscopy (Fig. 1. 2 and Table 1. 1) 
Saline-injected rats 
The saline-injected hippocampus showed light labeling for cholesterol (Fig. 
1. 2A). The low level of staining may be due to the fact most of the cholesterol in 
the brain is associated with cellular membranes and hidden within the 
phospholipid bilayer of the membranes (Ong et al. 2003). Light labeling for 
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cholesterol 24-hydroxylase (Fig. 1. 2B) was also observed. Labeling was 
observed in the cell bodies and dendrites of pyramidal neurons and punctate 
profiles in the neuropil. 
 
Kainate-injected rats 
Three days after kainate injection 
 Loss of neurons was observed in fields CA1 and CA3 of the hippocampus 
in Nissl stained sections (data not shown). The loss was more extensive on the 
side of the kainate injection than on the contralateral side. An increase in 
cholesterol immunoreactivity compared to saline-injected rats was observed in 
the affected CA fields (Fig. 1. 2C). The increased cholesterol staining was 
observed in the cell bodies and apical dendrites of pyramidal neurons and 
diffusely throughout the neuropil of the affected areas. In contrast to the 
increased immunoreactivity to cholesterol, decreased immunoreactivity to 
cholesterol 24-hydroxylase (Fig. 1. 2D) was observed in neurons of the affected 
CA field at this time. 
 
One to two weeks after kainate injection 
 Loss of neurons, and large numbers of glial cells were observed in fields 
CA1 and CA3 of the hippocampus as judged by Nissl staining. A further increase 
in cholesterol immunoreactivity compared to 3 day post-kainate-injected 
hippocampus was observed in the affected CA fields (Fig. 1. 2E). The number of 
cholesterol positive neurons was significantly greater in the 1 week (919 ± 104 
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cells / mm2) and 2 week (1018 ± 145 cells / mm2) post-kainate-injected rats, 
compared to saline-injected rats (0 ± 0 cells / mm2) (Table 1. 1). The increased 
cholesterol staining was observed in the cell bodies and apical dendrites of 
pyramidal neurons of the affected areas (Fig. 1. 2E). 
 An increased immunoreactivity to cholesterol 24-hydroxylase (Fig. 1. 2F) 
was observed in glial cells in the affected CA fields at this time. The number of 
cholesterol 24-hydroxylase positive glial cells was significantly greater in the 1 
week (1312 ± 195 cells / mm2) and 2 week (1815 ± 225 cells / mm2) post-kainate-
injected rats, compared to saline-injected rats (0 ± 0 cells / mm2) (Table 1. 1). 
The labeled cells had large diameter processes that tapered gradually from the 
cell bodies. They were shown to be astrocytes by electron microscopy and 
double immunofluorescence labeling with GFAP (see below). 
 No increase in cholesterol 24-hydroxylase immunoreactivity in glial cells 
was observed in areas of the hippocampus, or other parts of the brain that were 
unaffected by the kainate injections (data not shown). 
 
Four weeks after kainate injection 
 Little immunoreactivity to cholesterol was observed in the degenerating 
CA field at this time (Fig. 1. 2G), and the number of cholesterol positive neurons 
was significantly less than at earlier post-injection time intervals (Table 1. 1). The 
number of cholesterol 24-hydroxylase immunoreactive cells was similarly fewer, 
compared to that at 1 week or 2 week post-kainate injection (Fig. 1. 2H; Table 1. 
1). 
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 3. 2. 2. Electron microscopy (Fig. 1. 3A, B) 
Dense staining for cholesterol 24-hydroxylase was observed in glial cells, 
in the 2 week post-kainate-injected rats. The glial cells had large cell bodies with 
irregular cell outlines. The nucleus contained evenly dispersed fine 
heterochromatin clumps, and absence of dense marginated heterochromatin on 
the inner aspect of the nuclear envelope. The cytoplasm contained dense 
bundles of glial filaments. They thus had features of astrocytes (Fig. 1. 3A, B). 
 
3. 2. 3. Double immunofluorescence labeling of cholesterol 24-hydroxylase 
and GFAP (Fig. 1. 3C, D) 
Dense staining for cholesterol 24-hydroxylase in glial cells in the 2 week 
post-kainate-injected rats. The glial cells had large cell bodies with irregular cell 
outlines and were double immunolabeled for GFAP, confirming their identity as 
astrocytes (Fig. 1. 3C, D). The cholesterol 24-hydroxylase and GFAP stainings 
merged and showed that cholesterol 24-hydroxylase was only present in 
astrocyes at this time. 
 
3. 3. GC/MS analysis of cholesterol and oxysterols in the kainate-injected 
rat hippocampus (Table 1. 2) 
 Kainate injection resulted in significantly greater levels of cholesterol at 1 
week (63.0 ± 10.2 µg/mg), 2 weeks (98.6 ± 16.7 µg /mg) and 4 weeks (67.0 ± 4.2 
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µg /mg) after injection, compared to the saline-injected rats (23.0 ± 15.8 µg/mg) 
(Table 1. 2).  
 Significantly greater levels of 24-hydroxycholesterol were also observed at 
1 week (26.2 ± 6.3 ng/mg) and 2 weeks (30.1 ± 4.9 ng/mg) after kainate injection, 
compared to the saline-injected rats (7.2 ± 5.4 ng/mg) (Table 1. 2). The level of 
24-hydroxycholesterol returned to baseline level, and was not significantly 
greater than that of the saline-injected rats, at 4 weeks after kainate injection 
(Table 1. 2). 
 The level of 7-ketocholesterol was also significantly greater at 2 weeks 
(4.2 ± 0.9 ng/mg) after kainate injection, compared to saline injection (1.4 ± 0.4 
ng/mg) (Table 1. 2). Very low or undetectable levels of cholesterol epoxides, and 
25-hydroxycholesterol were found in the hippocampi of the kainate or saline-
injected rats. 
 
3. 4. Effect of lovastatin on cholesterol and oxysterol concentrations after 
kainate injury (Table 1. 3 and 1. 4) 
3. 4. 1. In vivo analyses (Table 1. 3) 
 Systemic administration of lovastatin resulted in significantly lower 
cholesterol and oxysterol levels in the hippocampus after kainate injection. The 
level of cholesterol in the 1 week post-kainate plus lovastatin injected rats was 
41.6 ± 16.0 µg/mg (Table 1. 3). This was significantly less than that of the kainate 
plus vehicle injected rats (67.6 ± 15.6 µg/mg, Table 1. 3), and approximately 65% 
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of the increase in cholesterol level after kainate treatment was blocked by 
lovastatin. 
 Lovastatin injection also resulted in significantly lower levels of 24-
hydroxycholesterol, in the kainate plus lovastatin injected rats (7.2 ± 2.9 and 11.6 
± 3.0 ng/mg at 1 week and 2 weeks postinjection respectively) compared to the 
kainate plus vehicle injected rats (23.1 ± 10.6 and 27.2 ± 7.8 ng/mg) (Table 1. 3). 
This effect was even more pronounced than that of cholesterol, and 
approximately 85% of the increase in 24-hydroxycholesterol after kainate 
treatment was blocked by lovastatin. 
 The level of 7-ketocholesterol in the kainate plus lovastatin injected rats 
(2.0 ± 0.9 ng/mg) was comparable to that of the kainate plus vehicle injected rats 
(2.9 ± 1.1 ng/mg) at 1 week after kainate injection, but was significantly lower 
compared to the kainate plus vehicle injected rats at 2 weeks after kainate 
injection (1.4 ± 0.2 ng/mg compared to 3.8 ± 0.8 ng/mg) (Table 1. 3). 
 
3. 4. 2. In vitro analyses (Table 1. 4) 
The changes in cholesterol and oxysterol levels after kainate / kainate plus 
lovatstatin treatment in vivo were also observed in vitro, although the absolute 
levels of cholesterol and oxysterols per weight of “slice tissue” was much lower 
than the brain. This could be due to increased extracellular space in the slices. 
Kainate treatment of hippocampal slice cultures also resulted in significantly 
greater levels of cholesterol, 24-hydroxycholesterol and 7-ketocholesterol, 
compared to the untreated slices (Table 1. 4). The levels of cholesterol and 
 61
oxysterols in the kainate plus lovastatin treated slices were significantly lower 
compared to the kainate plus vehicle treated slices (Table 1. 4). 
 
3. 5. Effect of lovastatin on neuronal survival after kainate injury (Fig. 1. 4 
and 1. 5) 
3. 5. 1. In vivo analyses (Fig. 1. 4) 
 Systemic administration of lovastatin partially protected hippocampal 
neurons after kainate injection as shown by representative Nissl stained sections 
(Fig. 1. 4A). Nissl stained sections showed 48.9 ± 10.6% cell survival in the 
kainate plus lovastatin injected rats. This was significantly more than the 17.0 ± 
8.7% uninjured neurons in the kainate plus vehicle injected rats (Fig. 1. 4B). 
MAP2 immunostained sections similarly showed greater proportion of uninjured 
neurons (47.3 ± 5.7 %) in the kainate plus lovastatin injected rats, compared to 
the kainate plus vehicle injected rats (19.2 ± 9.6%, Fig. 1. 4B). 
 
3. 5. 2. In vitro analyses (Fig. 1. 5) 
 Lovastatin also partially protected hippocampal neurons from kainate 
injury in slice cultures. Significantly lower MAP2 positive neuronal cells in fields 
CA1 and CA3 of the hippocampus were detected after kainate treatment, 
compared to the untreated slices (Fig. 1. 5A, B). Slices that had been treated 
with the kainate plus lovastatin showed significantly lower neuronal loss, 
compared to those treated with the kainate plus vehicle (Fig. 1. 5A, B). The 
protective effect of lovastatin was confirmed by detection of lower LDH activity in 
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the culture media of kainate plus lovastatin treated slices (50.9 ± 10.2% of total 
LDH release), compared to kainate plus vehicle treated slices (75.2 ± 8.3% of 
total LDH release) (Fig. 1. 5C).  
 
3. 6. Effect of 24-hydroxycholesterol on neuronal injury (Fig. 1. 6) 
In vitro analyses (Fig. 1. 6) 
 Treatment of the lower concentration of 24-hydroxycholesterol (15 µM) 
had no toxic effect on cultured hippocampal slices as shown by MAP2 stained 
sections (Fig. 1. 6A). In contrast, the higher concentration of 24-
hydroxycholesterol (50 µM) showed significantly fewer number of MAP2 positive 
neuronal cells in both CA1 and CA3 of the cultured hippocampus, compared to 
the untreated slices (Fig. 1. 6A, B). 
 24-Hydroxycholesterol induced neuronal injury was confirmed by the 
detection of increased LDH release in the culture media of the 24-
hydroxycholesterol (50 µM) treated slices, compared to the vehicle treated slices 
(Fig. 1. 6C). Treatment with 7-ketocholesterol (50 µM) also resulted in toxicity 
(Fig. 1. 6C). 
 
4. Discussion 
 Increased cholesterol immunoreactivity was detected in the degenerating 
CA fields of the hippocampus after kainate lesions, using a specific antibody to 
cholesterol. The cholesterol labeling was observed in the cell bodies and 
dendrites of pyramidal neurons, which are known to degenerate after kainate 
 63
injury (Sandhya et al. 1998). An increased immunolabeling of the oxysterol 
biosynthetic enzyme, cholesterol 24-hydroxylase was also observed in glial cells, 
in the affected areas. Electron microscopy confirmed that the glial cells had 
dense bundles of glial filaments, whilst double immunofluorescence labeling 
showed that cholesterol 24-hydroxylase positive glial cells were double labeled 
with GFAP, confirming that they were astrocytes. 
 The increase in cholesterol levels after kainate injury was confirmed by 
GC/MS analysis. A significant elevation in cholesterol levels was detected at 1 
week, 2 weeks, and 4 weeks after kainate injection, compared to saline-injected 
controls. Similar increases in cholesterol were detected in hippocampal slice 
cultures after kainate treatment. The technique of GC/MS measures the absolute 
amount of cholesterol in tissue samples, regardless of whether it is present within 
cell membranes, or free in the cytosol. Since little cholesterol is thought to enter 
the brain from the bloodstream (Dietschy and Turley 2004), the increase in brain 
cholesterol that is detected by this method therefore indicates de novo 
cholesterol synthesis. Increases in 24-hydroxycholesterol and 7-ketocholesterol 
levels were also detected by GC/MS after kainate injury, in vivo and in vitro. The 
in vitro results suggest that the increased cholesterol and oxysterols in brain 
tissue after kainate injury may be a consequence of increased cholesterol 
synthesis and cholesterol 24-hydroxylase expression in the degenerating brain 
tissue, and not only or primarily uptake from the bloodstream. This notion is 
supported by a previous study which found that most of the 24-
hydroxycholesterol in the serum is derived from the brain (Björkhem et al. 1998). 
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 The present study adds to our previous study, which showed that there is 
increased cholesterol and oxysterol levels in the hippocampus at short time 
intervals (3 days) after kainate injury (Ong et al. 2003). In this study, we showed 
that there were further significant increases in cholesterol, 24-hydroxycholesterol 
and 7-ketocholesterol levels in the degenerating hippocampus, at later time 
points, i.e. two weeks after the initial excitotoxic insult. The increases in 
cholesterol and oxysterols followed a similar pattern, increasing up to two weeks 
after kainate injection, followed by a decrease to near pre-lesion levels at four 
week post-injection. Other oxysterols such as cholesterol 5 alpha, 6 alpha-
epoxide, cholesterol 5 beta, 6 beta-epoxide, and 25-hydroxycholesterol were also 
analyzed in our samples, but these were not detected. 
 Neurotoxic effects of cholesterol metabolites have been reported recently 
(Nelson and Alkon 2005). 24-hydroxycholesterol and 7-ketocholesterol are toxic 
to cultured cerebellar granule neurons SH-SY5Y human neuroblastoma cells 
(Chang and Liu 1998; Kolsch et al. 2001). 24-hydroxycholesterol and 7-
ketocholesterol produce neuronal death (apoptosis) by caspase-3 activation, 
DNA fragmentation, and decreasing mitochondrial membrane potential (Kolsch et 
al. 1999; Lizard et al. 2005). Our recent studies also showed that 7-
ketocholesterol, cholesterol 5 alpha, 6 alpha-epoxide and cholesterol 5 beta, 6 
beta-epoxide were neurotoxic to pyramidal neurons in slice preparations of the 
rat hippocampus (Ong et al. 2003). The oxysterols, together with other factors 
such as iron-induced free radical damage (Wang et al. 2002), might contribute to 
increasing neuronal death in the hippocampus with time after kainate injury 
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(Sandhya et al. 1998). The toxicity of 24-hydroxycholesterol has been reported to 
be equal to that of 7-ketocholesterol in SH-SY5Y cells (Kolsch et al. 1999).  
 Slice cultures were treated with low (15 µM) and high (50 µM) 
concentrations of 24-hydroxycholesterol, to determine its possible neurotoxicity 
on hippocampal neurons. These concentrations were chosen based on 24-
hydroxycholesterol levels detected in vivo (~ 7.2 ng/mg tissue in the saline-
injected hippocampus and ~ 26.2 ng/mg tissue in the 1 week post-kainate-
injected hippocampus), and assuming a specific gravity of 1.05 g/cm3 (Morano 
and Seibyl 2003). The results showed that the lower concentration of 24-
hydroxycholesterol (15 µM or ~7.2 ng/mg tissue) was not toxic to hippocampal 
neurons, whereas the higher concentration (50 µM or ~26.2 ng/mg tissue) was 
neurotoxic. These results suggest that the level of 24-hydroxycholesterol 
encountered in vivo after kainate injury was sufficient to cause neuronal damage. 
 The effect of lovastatin on brain oxysterol levels and neuronal survival 
after kainate injury was also investigated. Rats that had been injected with 
kainate plus lovastatin showed lower levels of cholesterol, 24-hydroxycholesterol, 
and 7-ketocholesterol at 1 and 2 weeks after injection, compared to rats injected 
with kainate and vehicle. Interestingly, the level of 24-hydroxycholesterol was ~ 
7.2 ng/mg tissue (non-toxic range) after lovastatin treatment. This could be 
related to an observed protective effect of lovastatin on hippocampal neurons 
after kainate treatment. Nissl-stained, or MAP2 immunostained sections showed 
significantly lower neuronal death in the hippocampus, in kainate plus lovastatin 
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injected rats, compared to kainate plus vehicle injected rats. Lovastatin was also 
found to show neuroprotective effect on kainate-treated hippocampal slices. 
 Although high concentrations (10–25 µM) of lovastatin can suppress cell 
proliferation and induce apoptosis in various cell lines (Choi and Jung 1999; 
Crick et al. 1998; Garcia-Roman et al. 2001), low concentrations (4 µM) of 
lovastatin did not affect cell viability of cultured hippocampal neurons (Chou et al. 
2003; Fassbender et al. 2001). The concentration of lovastatin (1 µM) used in the 
present study is therefore unlikely to cause cellular injury. The findings of 
neuroprotective effect of lovastatin in slice cultures support the notion that 
inhibition of excess cholesterol synthesis could have a neuroprotective effect, 
apart from its effects on the microvasculature (see below). Together, the above 
findings suggest that increased brain cholesterol synthesis and oxysterol 
formation play a role in propagation of neuronal death after kainate injury. 
 The findings of the present paper may have implications in 
neuropathology. The use of statins has been reported to reduce the risk of AD 
(Jick et al. 2000; Wolozin et al. 2000), and also improve the outcome after stroke 
(Jacobs 2004; Vaughan 2003). Statins have also been shown to protect cortical 
neurons from excitotoxicity in cell culture (Zacco et al. 2003).There are several 
ways in which statins could exert their beneficial effects. One possibility is that 
statins might upregulate brain endothelial nitric oxide synthase, thus increasing 
blood flow, inhibiting platelet aggregation, and improving neurologic outcome 
(Amin-Hanjani et al. 2001; Vaughan et al. 2001). A second possibility is that 
statins might have anti-inflammatory actions including reducing interleukin-1 and 
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tumor necrosis factor production, thus inhibiting the consequences of neuronal 
damage (Balduini et al. 2003). A third possibility is that statins may enhance 
brain plasticity by increasing vascular endothelial growth factor, angiogenesis, 
endogenous cell proliferation and neurogenesis, thus improving functional 
outcome after neuronal injury (Chen et al. 2003). A fourth possibility is that 
neuroprotective effects of statins may be related to preservation of copper/zinc 
superoxide dismutase activity (Kumagai et al. 2004). A fifth possibility, in view of 
the present study, is that the neuroprotective effect of statins may be related to 
decreased cholesterol and oxysterol synthesis in the brain areas undergoing 
neurodegeneration / neuroinflammation. It is to be noted, however, that severe 
depletion of cholesterol in the brain (> 23% by use of experimental compounds, 
compared to lovastatin, < 10%) could result in seizures (Serbanescu et al. 2004). 
Further studies are necessary to elucidate changes in brain oxysterols, and 



















 II. Expression, activity, and role of serine 




Ceramides or N-acylsphingosines are components of distinct domains or 
rafts, which serve the spatial organization of signaling molecules in the cell 
membrane. They can be generated by hydrolysis of sphingomyelin through the 
action of sphingomyelinases in cellular membranes (reviewed in Marchesini and 
Hannun 2004). Surface acid sphingomyelinase is activated by receptors or stress 
stimuli and generates ceramide that fuse small rafts to form large ceramide-
enriched membrane platforms. The latter cluster receptor molecules and recruit 
intracellular signaling molecules to aggregated receptors (reviewed in Gulbins 
and Li 2006). Neutral, membrane-bound Mg2+-independent sphingomyelinase 
activity is increased in response to TNFα, heat stress, ischemia/reperfusion, 
arachidonic acid, and glutathione depletion (Liu et al. 1998; reviewed in Levade 
and Jaffrezou 1999). 
 Besides sphingomyelin breakdown, ceramides could be generated by de 
novo synthesis. The first reaction in the biosynthetic pathway consists of 
condensation of serine and palmitoyl CoA, a reaction catalyzed by serine 
palmitoyltransferase (SPT). This enzyme consists of heterodimers of 53-kDa 
regulatory SPT1 and catalytic 63-kDa SPT2 subunits bound to the endoplasmic 
reticulum (Hanada et al. 1997; Hanada 2003). The resulting keto-sphinganine is 
reduced and acylated to dihydroceramide, and desaturated to ceramide 
(reviewed in Perry 2002). Ceramides could also be formed from sphingosine 
through the action of (dihydro)ceramide synthase (sphingosine N-
acyltransferase). Ceramide biosynthesis is activated by free palmitoyl CoA, TNFα, 
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and chemotherapeutic agents, and could lead to apoptosis (Paumen et al. 1997; 
Xu et al. 1998). 
Increased ceramide levels have been detected in the brains of patients 
with Alzheimer's disease (Han et al. 2002; 2005; Cutler et al. 2004b; Satoi et al. 
2005) and HIV dementia (Haughey et al. 2004). Elevated levels of ceramide have 
also been detected in the brain after cerebral ischemia (Herr et al. 1999; Nakane 
et al. 2000; Takahashi et al. 2004; Ohtani et al. 2004) and status epilepticus 
(Mikati et al. 2003). Although previous studies have demonstrated a role for 
sphingomyelinase activity in ceramide accumulation during neurodegeneration 
(Yu et al. 2000; Alessenko et al. 2004), relatively little is known about possible 
contributions from ceramide biosynthetic activity. It has been suggested that 
sphingolipid biosynthesis is a necessary but potentially dangerous pathway that 
could lead to cell death (Merrill 2002). 
Our previous study has shown significant increases in 16:0, 18:0, 20:0, 
22:0 and 24:1 ceramide species and decreases in sphingomyelin species in the 
rat hippocampus after intracerebroventricular injection of the excitotoxin, kainate 
(Guan et al. 2006). The purpose of the present study is to elucidate the 
expression and activity of SPT in the rat hippocampus after kainate injury. 
Possible contributions of this enzyme to ceramide accumulation and neuronal 
injury after kainate treatment were also elucidated using hippocampal slice 
cultures. 
 
2. Materials and Methods 
 71
2. 1. Animals and intracerebroventricular kainate injection  
 This was carried out as described in Chapter II, I. 2. 1 (Page 41).  
 
2. 2. SPT expression by Western blot analyses 
This was carried out as described in Chapter II, I. 2. 2 (Page 42). The 
PVDF membrane was then incubated overnight in primary antibody, a rabbit 
polyclonal antibody to SPT (Cayman 10005260, MI, USA, diluted 1 µg/ml in Tris 
buffered saline [TBS]). The affinity purified antibody to SPT was raised against 
amino acids 548-562 of the human SPT catalytic subunit, SPT2. 
Immunoreactivity was visualized using a chemiluminescent substrate 
(Supersignal West Pico, Pierce, Rockford, IL, USA). Equivalent protein loading 
was confirmed by re-probing of membrane with antibody to β-actin (Sigma, St 
Louis, MO, USA). Films were scanned and the densities of the bands measured 
using the Quantity One software (BioRad, CA). The densities of the SPT bands 
were normalized against those of β-actin and the ratios calculated. Possible 
significant differences in the mean ratios between the kainate and saline treated 
animals were analyzed using 1 way ANOVA with Bonferroni’s multiple 
comparison post-hoc test. P < 0.05 was considered significant. 
 
2. 3. SPT activity assay 
 Kainate-injected rats were sacrificed at 3 days and 2 weeks post-injection 
(8 rats at each time point. Controls consisted of saline-injected rats of 2 weeks 
post-injection, 6 rats). The animals were deeply anesthetized with an 
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intraperitoneal injection of Nembutal and decapitated. The right hippocampus 
was then rapidly removed. Material from two hippocampi were pooled as a single 
sample for analysis. SPT activity was assayed in microsomal fractions of the 
hippocampi as previously described (Merrill et al. 1985). The reaction mixture 
consisted of 100 mM Hepes (pH 8.3, Sigma), 5 mM DTT, 2.5 mM EDTA, and 50 
µM pyridoxal phosphate (Sigma). Microsomal proteins (100-200 µg), 150 µM 
palmitoyl-CoA (Sigma) and 1 mM L-[3H] serine (PerkinElmer, Waltham, Ma, USA) 
were added to the reaction mixture and incubated at 37 °C for 10 min. The 
reaction was terminated by addition of 0.2 ml of 0.5 M NH4OH on ice. This was 
followed by addition of 1.5 ml of chloroform/methanol (1:2, v/v), 2 ml of 0.5 M 
NH4OH, and 50 µg of sphinganine (Sigma) as a carrier. The aqueous phase was 
discarded, and the organic phase rinsed twice with 2 ml of water. A sample (0.8 
ml) was then obtained and dried. Radioactivity was quantified using scintillation 
counting (Beckman, Fullerton, CA, USA). To correct for radioactivity that may not 
have been due to SPT activity, control assays were performed with each sample 
in the absence of palmitoyl-CoA. SPT activity was expressed as product 
formed/min·mg protein. Possible significant differences in mean SPT activity of 
samples from kainate or saline treated rats were analyzed using 1 way ANOVA 
with Bonferroni’s multiple comparison post-hoc test. P < 0.05 was considered 
significant. 
 
2. 4. SPT immunohistochemistry 
2. 4. 1. Immunoperoxidase labeling 
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 This was carried out as described in Chapter II, I. 2. 3. 1 (Page 43). The 
sections were then incubated overnight with primary antibody, a rabbit polyclonal 
a rabbit polyclonal antibody to SPT (Cayman, diluted to 1 µg/ml in PBS). Control 
sections were incubated with pre-immune rabbit serum or SPT immunizing 
peptide-absorbed antibody (Cayman) instead of primary antibody. The latter 
were prepared by incubating 20 µg/ml of SPT immunizing peptide with 1:1000 
dilution of SPT antibody overnight, followed by centrifugation, and collection of 
the supernatant for immunostaining. They showed absence of labeling. 
Quantitation of SPT labeled cells was carried out as described in Chapter 
II, I. 2. 3. 2 (Page 44). 
 
2. 4. 2. Double immunofluorescence labeling 
 This was carried out as described in Chapter II, I. 2. 3. 4 (Page 45). The 
sections were then incubated overnight with polyclonal antibodies to SPT (diluted 
to 1 µg/ml in PBS) and mouse monoclonal antibody to GFAP (Chemicon, 
Temecula, CA, USA, diluted 1:1000). The sections were then washed three times 
in PBS, and incubated for 1 h at room temperature in 1:200 dilution of fluorescein 
isothiocyanate (FITC)-conjugated goat anti-mouse IgG, and Cy3-conjugated goat 
anti-rabbit IgG (Chemicon). They were mounted and examined using an 
Olympus FluoView FV500 confocal microscopy. Control sections incubated with 
SPT immunizing peptide-absorbed antibody or pre-immune rabbit serum instead 
of primary antibody. They showed absence of labeling. 
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2. 4. 3. Electron microscopy 
 This was carried out as described in Chapter II, I. 2. 3. 3 (Page 45). 
 
2. 5. Hippocampal slice cultures 
 This was carried out as described in Chapter II, I. 2. 4 (Page 46). 
 
2. 6. Electrospray ionization mass spectrometry (ESI-MS) 
 Hippocampal slices were treated with 100 µM kainate for 3 hours, followed 
by treatment with SPT inhibitors, ISP-1 (myriocin) (Sigma, M1177, 100 nM) or L-
cycloserine (Sigma, 30018, 10 µM); a ceramide synthase inhibitor, fumonisin B1 
(Sigma, F1147, 10 µM); or a neutral sphingomyelinase inhibitor, GW4869 (Sigma, 
D1692 10 µM) for 24 h. Controls consisted of untreated slices. The 
concentrations of ISP-1 (Furuya et al. 1998; Cutler et al. 2004b), fumonisin B1 
(Merrill et al. 1993) and GW4869 (Luberto et al. 2002) have previously been 
shown to be effective in inhibiting the respective enzymes in vitro. 
 Each sample consisted of material pooled from 8-12 slices. Lipids were 
extracted using the protocol of Bligh and Dyer (1959). Briefly, 400 µl of 
chloroform-methanol (1:2, v/v) were added to 10 mg hippocampal slice 
homogenate and 1 µg of internal standards, C19-CER and C12-SPM were added. 
After 10 min incubation on ice, 300 µl of chloroform and 200 µl of 1 M 
hydrochloric acid (HCl) were added to the mixture and the lipids were isolated 
from the organic phase following centrifugation. The sample was vacuum dried 
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(Thermo Savant SpeedVac, Thermo, Waltham, MA, USA), resuspended in 1 ml 
of chloroform-methanol (1:1, v/v) and used for analysis. 
 Quantification of individual molecular species was performed using 
multiple reaction monitoring (MRM) with an Applied Biosystems 4000 Q-Trap 
mass spectrometer (Applied Biosystems, Foster City, CA). Typically 10 µl of 
samples were injected for analysis. The inlet system consisted of an autosampler 
and a pump and chloroform-methanol (1:1, v/v) at a flow rate of 200 µl/min was 
used as the mobile phase. In these experiments, the first quadrupole, Q1, was 
set to pass the precursor ion of interest to the collision cell, Q2, where it 
underwent collision induced dissociation. The third quadruple, Q3, was set to 
pass the structure specific product ion characteristic of the precursor lipid of 
interest. Each individual ion dissociation pathway was optimized with regard to 
collision energy to minimize variations in relative ion abundance due to 
differences in rates of dissociation. Ceramide or sphingomyelin levels were 
calculated relative to relevant internal standards. The mean of 4 samples from 
each treatment group was calculated, and possible significant differences 
between the means analyzed using 1 way ANOVA with Bonferroni’s multiple 
comparison post-hoc test. P < 0.05 was considered significant. 
 
2. 7. Quantification of cellular injury by microtubule associated protein 
(MAP2) immunolabeling 
 Hippocampal slices were treated with 100 µM kainate for 3 hours, followed 
by treatment with ISP-1 (1 nM, 10 nM and 100 nM) or LCS (0.1, 1, 10, and 100 
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µM). Controls consisted of untreated slices. The above concentration of kainate 
has previously been shown to be toxic to neurons in hippocampal slices (Lu et al. 
2001). The slices were fixed at 24 h after treatment by immersion in 4% 
paraformaldehyde in 0.1 M phosphate buffer (pH 7.4). Polytetrafluoroethylene 
membranes were cut from the culture plate inserts, washed, and immunostained 
with the attached slices using an antibody to MAP2 (Sigma, diluted 1:500) to 
demonstrate viable neurons. The number of MAP2 positive cells in 
representative regions of CA fields of the hippocampal slices was then counted 
as described in Chapter II, I. 2. 3. 2 (Page 44). The mean of 6-8 slices in each 
treatment group was calculated, and possible significant differences in the means 
analyzed using 1 way ANOVA with Bonferroni’s multiple comparison post-hoc 
test. P < 0.05 was considered significant. 
 
2. 8.  Quantitation of cellular injury by lactate dehydrogenase (LDH) assay 
 Hippocampal slice cultures were treated with 100 µM kainate for 3 hours, 
followed by treatment with ISP-1 (100 nM), LCS (10 µM), fumonisin B1 (10 µM), 
or GW4869 (10 µM) for 24 h. Controls consisted of untreated slices. Media from 
three culture wells (4 slices in each well) was pooled as a single sample, and 
analyzed using a LDH cytotoxicity detection kit (Roche, Mannheim, Germany) as 
follows: neuronal death = [(A-Min)/(Max- Min)]x100, in which A is LDH activity 
measured in media of test condition, Max is maximum LDH release after 3 h 
treatment with Triton X-100, defined as 100% of cell death, Min is the minimum 
LDH activity in media of untreated slices. The mean of four samples in each 
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treatment group was calculated, and possible significant differences between the 
means analyzed using 1 way ANOVA with Bonferroni’s multiple comparison post-
hoc test. P < 0.05 was considered significant. 
 
3. Results 
3. 1. SPT expression by Western blot analyses (Fig. 2. 1A, B) 
The affinity purified polyclonal antibody to SPT detected a single band at 
~65 kDa in saline- and kainate-injected rat hippocampus, consistent with the 
molecular weight of the SPT2 subunit (Batheja et al. 2003; Hanada 2003) (Fig 2. 
1A). The antibody to β-actin reacted against a band at ~42 kDa. SPT protein 
level was similar between kainate- and saline-injected rats at 1 or 3 day post-
injection, but was significantly greater in kainate injected rats at 1 and 2 weeks 
post-injection (Fig. 2. 1A, B). 
 
3. 2. SPT activity assay (Fig. 2. 1C). 
SPT activity was 28.4 ± 1.9 pmol/min·mg in the saline-injected rat 
hippocampus (Fig. 2. 1C). This is consistent with the results of a previous study 
(30.1 ± 4.2 pmol/min·mg in the normal rat brain) (Merrill et al. 1985). SPT activity 
was significantly increased at 2 weeks post-injection in kainate-injected rats 
compared to saline injected controls (Fig. 2. 1C). 
 
3. 3. SPT immunohistochemistry (Fig. 2. 2 and 2. 3; Table 2. 1) 
3. 3. 1.  Immunoperoxidase labeling (Fig. 2. 2 and Table 2. 1) 
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Control rats 
Light labeing for SPT (Fig. 2. 2A) was observed in pyramidal neurons in 
the CA fields of the hippocampus. 
 
Three day post-kainate injection 
 Loss of neurons was observed in fields CA1 and CA3 of the hippocampus 
in Nissl stained sections (data not shown). The damage was more extensive on 
the side of the kainate injection, but was also observed on the contralateral side, 
possibly due to diffusion of the toxin via the ventricular system. Also, unilateral 
excitotoxicity can drive the commissural projections of CA3, which can cause a 
contralateral excitotoxicity and cell death (Yasuda et al. 2001). The lesioned 
areas showed loss of SPT immunolabeling in neurons, but occasional labeling in 
glial cells (Fig. 2. 2B). 
 
One week post-kainate injection 
 Loss of neurons, and large numbers of glial cells were observed in fields 
CA1 and CA3 of the hippocampus in Nissl stained sections (data not shown). 
Increased labeling of glial cells was observed at this time (Fig. 2. 2C; Table 2. 1). 
The latter were double labeled with GFAP, a marker for astrocytes (see below). 
 
Two week post-kainate injection 
A further increase in number of SPT positive glial cells was observed at 
this time (Fig. 2. 2D, E; Table 2. 1). 
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 Four week post-kainate injection 
A decline in SPT (Fig. 2. 2F) immunoreactivity was observed, and the 
number of SPT immunolabeled glial cells was fewer than that at 2 week post-
kainate injection (Table 2. 1). 
 
3. 3. 2. Double immunofluorescence labeling (Fig. 2. 3A, B) 
Immunolabeling for SPT was observed in glial cells in the kainate-lesioned 
hippocampus. The latter were double immunolabeled for GFAP, a marker for 
astrocytes (Fig. 2. 3 A, B). 
 
3. 3. 3. Electron microscopy (Fig. 2. 3 C, D) 
 Dense immunoreactivity to SPT was observed in reactive glial cells at 2 
weeks after kainate lesions. The nucleus contained fine heterochromatin clumps 
and the cytoplasm contained dense bundles of glial filaments characteristic of 
astrocytes (Fig. 2. 3C, D). Immunoreactivity was also present in end feet around 
blood vessels (Fig. 2. 3C, D). 
 
3. 4. Role of SPT in kainate injury (Fig. 2. 4- Fig. 2. 6) 
3. 4. 1. Effect on ceramide and sphingomyelin concentrations (Fig. 2. 4) 
 A significant increase in 16:0, 18:0 and 20:0 ceramide species was 
detected after kainate treatment (Fig. 2. 4A). Slices treated with kainate plus ISP-
1, LCS, or fumonisin B1 showed significantly lower levels of several ceramide 
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species, compared to slices treated with kainate alone. LCS attenuated the 
kainate-induced increases in 16:0 and 20:0 ceramide, whereas ISP-1 and 
fumonisin B1 attenuated increases in 16:0, 18:0 and 20:0 ceramide. Slices 
treated with kainate plus GW4869 showed non-significant decrease in ceramide 
compared to slices treated with kainate alone (Fig. 2. 4A). 
 A trend to a decrease but non-significant was observed in several 
sphingomyelin species after kainate treatment. No change in sphingomyelin 
species was detected after treatment of slices with kainate plus inhibitors (Fig. 2. 
4B). Possible significant differences were analyzed using 1 way ANOVA with 
Bonferroni’s multiple comparison post-hoc test. P < 0.05 was considered 
significant.  
 
3. 4. 2. Effect on MAP2 immunolabeling (Fig. 2. 5) 
 Kainate treatment resulted in a significant decrease in MAP2 
immunoreactivity in the CA fields of hippocampal slices, compared to controls. 
Treatment of slices with 100 nM ISP-1 or 10 and 100 µM LCS significantly 
attenuated the kainate-induced decrease in MAP2 staining (Fig. 2. 5). 
 
3. 4. 3. Effect on lactate dehydrogenase (LDH) release (Fig. 2. 6). 
 Kainate treatment resulted in a significant increase in LDH activity in the 
culture media compared to controls (Fig. 2. 6). Significantly lower LDH activity 
was detected in the culture media after treatment with kainate plus ISP1, LCS, or 
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fumonisin B1, compared to treatment with kainate alone. No significant difference 
was detected after treatment with kainate plus GW4869 (Fig. 2. 6). 
 
4. Discussion 
 The present study aimed to determine the expression, activity, and 
possible role of the first enzyme in the ceramide biosynthetic pathway, SPT, after 
kainate-induced neuronal injury. Western blot analyses and enzyme activity 
assay were carried out to elucidate SPT expression and activity after 
intracerebroventricular kainate injections. SPT enzyme protein levels of the 
hippocampus remained at near baseline levels at 1-3 days after kainate 
injections, but increased significantly at 1 week and 2 weeks after kainate 
injection. The increase in enzyme protein was paralleled by significantly 
increased hippocampal SPT enzyme activity at two weeks post-kainate injection, 
compared to saline injected controls. 
 Immunohistochemical analyses showed baseline expression of SPT in 
neurons. This finding is consistent with a previous study which showed neuronal 
expression of the enzyme in the brain (Batheja et al. 2003). Kainate treatment 
resulted in decreased labeling in neurons but increased labeling in glial cells, in 
the affected CA fields. The number of SPT positive glial cells peaked at 2 weeks 
after kainate injection. The glial cells were double labeled for GFAP, confirming 
that they were astrocytes. Non-specific binding by the antibody is unlikely, since 
sections incubated with antigen-absorbed antibody showed absence of labeling. 
 In vitro studies were carried out using hippocampal slice cultures to 
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elucidate ceramide biosynthesis after kainate lesions. Kainate treatment resulted 
in significant increases in 16:0, 18:0 and 20:0 ceramide species. The greatest 
increase was in C18:0 ceramide. These results are similar to that observed after 
intracerebroventricular kainate injections (Guan et al. 2006). Slices which had 
been treated with kainate plus SPT inhibitors ISP-1 or LCS, or the ceramide 
synthase inhibitor fumonisin B1, showed significantly lower levels of 16:0, 18:0 
and 20:0 ceramide species, compared to those treated with kainate alone. 
Treatment with a neutral sphingomyelinase inhibitor GW4869 resulted in no 
significant difference. A trend to a decrease, but non-significant, was detected in 
sphingomyelin after kainate treatment. Together, these findings indicate a role for 
ceramide biosynthesis contributing to the ceramide increase after kainate injury 
although additional effects of sphingomyelinases cannot be excluded. 
 A possible effect of ceramide biosynthesis in kainate injury was then 
investigated. Neuronal injury was determined by quantitation of MAP2 
immunostaining of viable neurons in CA fields of hippocampal slices, and assay 
of LDH released into the culture media from damaged neurons. Addition of 
kainate to slices resulted in neuronal injury, as demonstrated by decrease in 
MAP2 immunolabeling of slices, but increase in LDH released into the culture 
media. Treatment of slices with kainate plus ISP-1 or LCS resulted in significantly 
reduced neuronal injury, compared to treatment with kainate alone. Treatment 
with GW4869 showed no significant protective effect. These results indicate that 
SPT might contribute to neuronal injury after kainate treatment. These findings 
are consistent with previous studies which showed that ISP-1 prevented A beta 
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induced death of hippocampal neurons (Cutler et al. 2004b). ISP-1 also 
attenuated ethanol-induced cell death in SK-N-SH neuroblastoma cells (Saito et 
al. 2005). ISP-1 or LCS could act by reducing ceramide biosynthesis in neurons 
or astrocytes even though decreased neuronal expression of SPT was observed 
after injury. Our data also showed significant kainate-induced cell death that was 
not inhibited by SPT inhibitors. This might be attributed to excitotoxicity / calcium 
mediated neuronal injury, which is well-known to play an important role in kainate 
injury (Mattson et al. 1991). 
Ceramide causes apoptotic and non-apoptotic cell death in cultured 
neurons depending on model system and experimental conditions (Brugg et al. 
1996; Sortino et al. 1999; Movsesyan et al. 2002; Kim et al.  2005). The C16:0 
ceramide has been reported to be more potent than ceramides of other chain 
lengths in inducing apoptosis (Osawa et al. 2005). The mechanism of ceramide 
action may include: (a) Ceramide-mediated clustering of membrane receptors, 
thus enabling membrane domains to be involved in induction of apoptosis by 
death receptors (Dobrowsky and Carter 1998; reviewed in Gulbins and Li 2006), 
(b) formation of ceramide-mediated large protein permeable channels on the 
outer membrane of mitochondria (Siskind 2005). This could facilitate the release 
of proapoptotic proteins including cytochrome c from mitochondria to the 
cytoplasm, and trigger the induction of mitochondrial-dependent intrinsic caspase 
pathway (Stoica et al. 2005). (c) Besides apoptosis, ceramides could produce 
non-apoptotic, caspase-independent cell death through activation of cytosolic 
phospholipase A2α (cPLA2α) in glial cells (Kim et al. 2005). Ceramide-1-
 84
phosphate could facilitate translocation and activation of cPLA2α directly and by a 
PKC-dependent pathway (Nakamura et al. 2006). This could lead to increased 
generation of arachidonic acid from membrane phospholipids, and formation of 
toxic lipid peroxidation products such as 4-hydroxynonenal (Farooqui et al. 2004). 
Further studies are necessary to elucidate effects of inhibition of SPT after 






















III. Effect of apolipoprotein D on neuronal survival, 
cholesterol and lipid oxidation product formation after 
kainate-induced neuronal injury 
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1. Introduction 
 Apolipoprotein D (apoD) is a 169-amino acid glycoprotein that was 
originally identified as a component of high-density plasma lipoproteins 
(McConathy and Alaupovic 1973). ApoD is not a typical apolipoprotein, but 
belongs to the lipocalin superfamily of transporter proteins that carry various 
small hydrophobic ligands (Flower 1996). ApoD is widely expressed in both 
neural and non-neural tissues (Boyles et al.1990a; Provost et al. 1990; Seguin et 
al.1994). It is present in neurolemma cells and endoneurial fibroblasts in 
peripheral nerves (Boyles et al. 1990b), and oligodendrocytes, astrocytes, and 
perivascular cells in the brain (Boyles et al. 1990a; Smith et al. 1990; Patel et al. 
1995; Navarro et al. 1998). 
A 40-fold accumulation of apoD has been detected in the extracellular 
space of regenerating crushed rat nerve (Spreyer et al. 1990).  An even more 
marked increase in apoD has also been reported in regenerating peripheral 
nerves of rabbits, and monkeys (Boyles et al. 1990a). Elevated apoD levels was 
present after experimental brain injury (Ong et al. 1997; Montpied et al. 1999, 
Franz et al. 1999; Terrisse et al. 1999), and in neurodegenerative conditions 
such as Alzheimer's disease (Terrisse et al. 1998; Thomas et al. 2003), 
Niemann–Pick type C disease (Suresh et al. 1998) and prion disease (Dandoy-
Dron et al. 1998).  
 ApoD has the ability to bind several small hydrophobic ligands, including 
arachidonic acid, cholesterol, progesterone, porphyrins and heme-related 
molecules (Lea 1988; Peitsch and Boguski 1990; Boyles et al. 1990b; Morais-
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Cabral et al. 1995; Patel et al. 1997). Although the exact physiological function 
for apoD in the brain is not known, the diversity of ligands transported by apoD 
suggests that it may have wide-ranging physiological cellular functions. 
The excitotoxin, kainate, is commonly used to induce neuronal injury in 
studies of diseases of the CNS. KA treatment results in neuronal death in rat 
brain (Pohle and Rauca 1994; Lan et al. 2000; Boldyrev et al. 1999). We have 
previously shown a marked increase of apoD expression in the rat hippocampus 
after neuronal injury induced by kainate (Ong et al. 1997). The increase in apoD 
is paralleled by decreases in phospholipid levels and increases in arachidonic 
acid and cholesterol levels in the degenerating hippocampus (Farooqui et al. 
2001, Guan et al. 2006; He et al. 2006). One possibility is that apoD may be 
upregulated in injured neurons as part of a cellular defense mechanism to bind 
and perhaps limit the increase in free arachidonic acid or cholesterol. The 
present study was therefore carried out to examine potential neuroprotective 
effects of apoD by regulating lipid abnormalities, in hippocampal slice cultures. 
The effect of oxidative stress on cultured fibroblasts from wild type and apoD 
knockout mice was also studied as a comparison.  
 
2. Materials and methods 
2. 1. hippocampal slice cultures 
 This was carried out as described in Chapter II, I. 2. 4 (page 46). After 
initial kainate treatment, cultures were incubated with 1) different concentrations 
of apoD, diluted in fresh serum-free medium 2) 10 µg/ml of apoD and 1:100 
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dilution of rabbit antibody to apoD, and 3) 10 µg/ml beta-lactoglobulin (BLG, 
Sigma). Beta-lactoglobulin is a lipocalin with limited affinity to cholesterol and 
arachidonic acid. Purified apoD protein from human breast cystic fluid was 
prepared by centrifugation at 35,000 g for 2 h, followed by dialysis of the 
aqueous phase against K2HPO4 10 mM pH 7.4, and hydroxyapatite in same 
buffer. ApoD elutes in the flow through and is concentrated on DEAE-agarose 
and eluted with 400 mM NaCl. Stock apoD and BLG (1 mg/ml) were dissolved in 
serum-free medium and sterilized through 0.22 µm filter for sterilization. Controls 
consisted of untreated slices. 
 
2. 2. Quantitation of cellular injury by MAP2 immunolabeling 
 This was carried out as described in Chapter II, II. 2. 7 (page 75).   
 
2. 3. Quantitation of cellular injury by LDH assay 
 This was carried out as described in Chapter II, II. 2. 8 (page 76).  
 
2. 4. GC/MS analysis 
2. 4. 1. Chemicals 
 High purity (> 99%) F2-isoprostanes (F2-isoPs), 8-iso-PGF2α (iPF2α-III), 
and deuterium-labeled heavy isotopes 8-iso-PGF2α-d4 (iPF2α-III-d4) and iPF2α-
VI-d4 were purchased from Cayman Chemical (Ann Arbor, MI, USA). Standards 
for cholesterol, 7-ketocholesterol, 5α-cholestane and ergosterol were purchased 
from Sigma (St Louis, MO, USA) and of at least 95% purity. 24S-
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hydroxycholesterol (non-deuterated) was purchased from Medical Isotopes 
(Pelham, AL, USA). 5α-cholestane and ergosterol were used as internal 
standards. Standard solutions of cholesterol, oxysterols, 5α-cholestane and 
ergosterol were diluted in ethanol. Formic acid (Lancaster, England), ammonium 
hydroxide, potassium hydroxide, butylated hydroxytoluene (BHT), hydrochloric 
acid (Merck, Darmstadt, Germany), and hexane (Tedia, Fairfield, OH, USA) were 
of analytical grade. Methanol (EM Science, Darmstadt, Germany) and ethyl 
acetate (Fisher Scientific, UK) were of HPLC grade. N,O-
bis(trimethylsilyl)trifluoroacetamide +1% trimethylchlorosilane (BSTFA+TMCS) 
silylating agent was obtained from Pierce Chemicals (Rockford, IL, USA). 
Pentafluorbenzylbromide (PFBBr) and N,N-diisopropylethylamine (DIPEA) were 
purchased from Sigma Chemicals. Oasis Mixed Anion Exchange (MAX) 
cartridges were from Waters Corp (Milford, MA, USA). 
 
2. 4. 2. Lipid extraction 
 This was carried out as described in Chapter II, I. 2. 5. 2 (Page 49)  
 
2. 4. 3. Lipid hydrolysis 
 2 ml of 0.5 M KOH (in 50% methanol) was added with 400 ng ergosterol 
and 10 µg 5α-cholestane, an internal standard for cholesterol and oxysterol 
analysis, and 20 µl mixed heavy isotopes (0.5 ng 8-iso-PGF2α-d4 and 0.5 ng 
iPF2α), an internal standard for F2-isoprostanes analysis, and the vial sealed 
under N2. The lipid extract was hydrolyzed at 23°C for 2 h in the dark. 
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 2. 4. 4. Mixed anion exchange solid phase extraction 
 2.7 ml formic acid (40 mM), 0.2 ml HCI (5 M) and 1 ml methanol were 
added and thoroughly mixed before loaded onto a 3 ml, 60 mg Oasis Mixed 
Anion Exchange (MAX) solid phase extraction column previously conditioned 
with 2 ml methanol and 2 ml formic acid (20 mM). The column was then washed 
with 2 ml 2% (v/v) ammonium hydroxide followed by 2 ml 40% methanol/formic 
acid. Cholesterol and oxysterols were eluted with 2 ml hexane followed by 2 ml 
ethyl acetate/hexane (30/70) and collected together into a glass tube, while 
isoprostanes are eluted with 1.6 ml ethyl acetate.  
 
2. 4. 5. Derivatization 
 The eluted solvent was evaporated under N2. Samples for cholesterol 
analysis were derivatized with 25 µl acetonitrile and 25 µl BSTFA with 1% TMCS 
for 30 min at room temperature and injected directly onto GC/MS. Samples for 
oxysterol analyses were derivatized with 50 µl acetonitrile and 50 µl BSTFA + 1% 
TMCS for 30 min at room temperature, evaporated to dryness under N2 and 
reconstituted in 30 µl undecane before injection into the GC/MS. Samples for F2-
isoprostanes were firstly derivatized with 15 µl DIPEA (10% v/v acetonitrile) and 
30 µl PFBBr (10% v/v acetonitrile) for 30 min then secondly derivatized with 20 µl 
acetonitrile and BSTFA with 40 µl 1% TMCS for 30 min at 40 0C for silylation of 
the F2-isoPs. Samples were evaporated to dryness under N2 and reconstituted in 
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30 µl undecane before injection onto GC/MS. GC/MS running will be described 
as below. 
 
2. 4. 6. GC/MS analysis of cholesterol and oxysterols 
  This was carried out as described in Chapter II, I. 2. 5. 5- 2. 5. 7 (Page 
50). 
 
2. 4. 7. GC/MS analysis of F2-isoprostanes 
 The derivatized samples were analyzed by a Hewlett-Packard 5973 mass 
selective detector interfaced with a Hewlett-Packard 6890 gas chromatograph, 
equipped with an automatic sampler and a computer workstation. The injection 
port and GC/MS interface were kept at 280 and 290 °C, respectively. The mass 
spectrometer was used in the negative chemical ionization (NCI) mode with the 
ion source and quadrapole at 150 and 106 °C, respectively, and the methane 
flow rate at 2 ml/min. Separations were carried out on a fused silica capillary 
column (30m x 0.2 mm i.d.) coated with cross-linked 5% phenylmethylsiloxane 
(film thickness 0.33 µm) (Agilent). Helium was the carrier gas with a flow rate of 1 
ml/min. Derivatized samples (1 µl) were injected splitless into the GC injection 
port. The column temperature was maintained at 170 °C for 2 min, and then 
increased to 275 °C at 15 °C /min, then held at 275 °C for 11 min. Finally 
temperature was raised to 295 °C at 25 °C /min and held for 3 min. Emission 
energy was 250 µA. Selected ion monitoring was performed to monitor the 
carboxylate ion (M-181: loss of pentafluorobenzyl, CH2C6F5) at ions m=z 569 for 
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8-iso-PGF2α and at m=z 573 for deuterium-labeled (8-iso-PGF2α-d4 and iPF2α-VI-
d4) internal standards. Quantitation was achieved by relating the peak area of the 
total F2-isoPs with the sum of the 2 different F2-isoPs’ internal standard peaks. 
Concentration values were expressed as total F2-isoPs per gram tissues and 
expressed as mean + standard deviation.  
 
2. 5. Statistical analysis 
 The results were subjected to statistical analyses, using 1 way ANOVA 
with Bonferroni’s multiple comparison post-hoc test and Student's t-Tests. P < 
0.05 was considered significant. 
 
3.  Results 
3. 1. Effect of apoD on kainate-induced injury (Fig.  3. 1- Fig. 3. 3) 
 Treatment of hippocampal slice cultures with kainate (100 µM) for 3h 
caused neuronal injury in the hippocampal field CA1 and CA3. This was shown 
by the light microscopic observation of fewer MAP2 immunostained pyramidal 
neurons in hippocampal CA fields of kainate-treated slices compared to that in 
the untreated control slices (Fig. 3. 1 and 3. 2A). In addition, kainate-induced 
neuronal death was confirmed by increase in LDH activity in the culture media of 
kainate-treated slices compared to untreated control slices (Fig. 3. 2B). 
 ApoD treatment resulted in a dose-dependent neuroprotective effect on 
the kainate-injured hippocampal slices. There were a greater number of MAP2 
immunostained pyramidal neurons in hippocampal CA fields of kainate and 10 
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µg/ml apoD, or kainate and 20 µg/ml apoD treated slices compared to the 
kainate-treated slices (Fig 3. 1). 10 µg/m ApoD protected about 53%, and 20 
µg/ml apoD protected about 37% kainate-injured neurons in the CA fields. The 
neuroprotective effect was not detected in the kainate plus 1 µg/ml apoD or 
kainate plus 5 µg/ml apoD treated slices (Fig. 3. 1). Further examination of MAP2 
immunostained pyramidal neurons in hippocampal subfields showed that post-
treatment with 10 µg/ml apoD produced protection in CA1 and CA3 (Fig. 3. 2 A). 
The effect of apoD on neuronal survival was further studied LDH assay. Post-
treatment of 10 µg/ml apoD significantly reduced LDH released from cultures 
after kainate treatment, confirming a neuroprotective effect of apoD (Fig 3. 2B). 
 In contrast to apoD, addition of the lipocalin, beta lactoglobulin (BLG), did 
not result in neuroprotection in the kainate-treated slices. Addition of apoD plus 
apoD antibody to slices also resulted in reduced neuroprotective effect compared 
to treatment with apoD alone (Fig. 3. 3) 
 
3. 2. Effect of apoD on F2-isoprostanes, cholesterol, and oxysterol levels in 
cultured hippocampal slices (Fig. 3. 4) 
 An increased level of the arachidonic peroxidation products, F2-isoPs were 
detected in the kainate-treated slices, compared to untreated controls. The 
elevation in F2-isoP level was modulated by treatment of slices with 10 µg/ml 
apoD (Fig. 3. 4A). Kainate treatment also resulted in significantly increased 
cholesterol, 7-ketocholesterol, and 24-hydroxycholesterol levels in slices, and 
these increases were similarly attenuated by apoD (Fig.  3. 4B, C, D). 
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 3. 3. Effect of apoD on F2-isoprostane and oxysterol levels in cultured 
fibroblasts after hydrogen peroxide treatment (Fig. 3. 5) 
 Similar levels of F2-isoPs were detected in untreated fibroblasts from wild 
type or apoD knockout mice. After treatment with hydrogen peroxide for 4 and 8 
h however, significantly greater increases in F2-isoP levels were detected in 
fibroblasts from apoD knockout mice, compared to those from the wild type mice 
(Fig. 3. 5 A). 
The levels of 7-ketocholesterol levels were also similar, between untreated 
fibroblasts from wild type- and apoD knockout mice, but significantly greater in 
the fibroblrasts from the apoD knockout mice, after treatment with hydrogen 
peroxide (Fig 3. 5C). No significant differences in cholesterol or 24-
hydroxycholsterol levels were detected between wild type and apoD knockout 
fibroblasts, either in the untreated state or after hydrogen peroxide treatment (Fig 
3. 5B, D). 
 
4. Discussion 
 ApoD is a member of the lipocalin family of transport proteins, with ability 
to sequester small hydrophobic ligands such as arachidonic acid and cholesterol. 
The latter may be related to physiological function of the lipocalin. The present 
study was carried out to elucidate potential effects of exogenous apoD on 
neuronal survival and lipid oxidation products in hippocampal slices cultures, 
after kainate treatment. Slice cultures preserve several characteristics of the 
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intrahippocampal circuitry observed in vivo. Addition of kainate to hippocampal 
has also been shown to result in cell death, similar to the effect of kainate in 
intact animals (Lu et al. 2001). The results showed that apoD treatment dose-
dependently resulted in protection of neurons against kainate-induced neuronal 
injury, as determined by MAP2 immunohistochemistry and assay of LDH 
released into the culture media. The neuroprotective effect of apoD was partially 
blocked by antibody to apoD. Neuroprotective effect was also not observed after 
application of another lipocalin, beta lactoglobulin, suggesting that the effect was 
perhaps specific to apoD. 
 There is increasing evidence that early alteration of lipid metabolism 
during injury may play a critical role in neuronal death (Relton et al. 1993; 
Geddes et al. 1997; Keller et al. 1997; Cutler et al. 2004b). Kainate treatment 
results in a rapid breakdown of phospholipids and accumulation of arachidonic 
acid (Farooqui et al. 2001). The increase in arachidonic acid is accompanied by 
increases in the level of its toxic lipid peroxidation product, 4-hydroxynonenal, 
suggesting that this could play a major role in neuronal death after kainate 
excitotoxicity (Ong et al. 1999; Lu et al. 2001). The present results showed that 
addition of apoD significantly modulated the levels of lipid peroxidation product 
F2-isoPs in hippocampal slice cultures after kainate treatment. The latter are 
stable decomposition products of arachidonic acid peroxidation, and one of the 
most reliable biomakers of oxidative stress (Roberts and Morrow 2000; Basu 
2004). The results suggest that the neuroprotective effect of apoD may be due to 
its ability to bind arachidonic acid, thus resulting in reduction of its lipid 
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peroxidation products. Although F2-isoPs were measured in this study due to 
their stability, it is possible that other more reactive and toxic lipid peroxidation 
products such as 4-hydroxynonenal (4-HNE) might also be reduced by apoD. 
 Another way in which apoD might exert its neuroprotective effect could be 
through binding to cholesterol. Our recent studies showed that there is an 
increased cholesterol synthesis in the hippocampus after kainate treatment (Ong 
et al. 2003; He et al. 2006). Since apoD is known to bind cholesterol (Patel et al. 
1995; Suresh et al. 1998), one possibility is that apoD may sequester excess 
cholesterol in the degenerating hippocampus after kainate treatment, and 
prevent the formation of its oxidation products. This may have a neuroprotective 
function, since excess cholesterol oxidation products such as 7-ketocholesterol 
or 24-hydroxycholesterol are known to be toxic to neurons (Kolsch et al. 2001, 
Chang et al. 1998; He et al. 2006). The present study support this hypothesis, by 
showing that apoD treatment significantly modulates kainate-induced increases 
in 7-ketocholesterol and 24-hydroxycholesterol levels in hippocampal slices. 
Increased sequestration of cholesterol by apoD could reduce the content of both 
7-ketocholesterol which is formed by direct oxidation of cholesterol (Miguet-
Alfonsi et al. 2002), and 24-hydroxycholesterol, produced by the brain specific 
enzyme, cholesterol 24-hydroxylase (Russell 2000). 
 Together, the ability of apoD to prevent the formation of kainate-induced 
F2-isoPs and oxysterols suggests that this lipocalin may be an important 
antioxidant protein in the brain. This was directly studied by comparing cell 
survival and lipid oxidation in fibroblasts from wild-type mice and apoD knockout 
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mice. Fibroblasts from apoD knockout mice showed reduced cell survival after 
hydrogen peroxide treatment. Similarly F2-isoP, cholesterol, 7–ketocholesterol 
and 24-hydroxycholesterol levels were detected in untreated fibroblasts from 
both wild type and apoD knockout mice. In contrast, treatment with hydrogen 
peroxide treatment for 4h and 8h resulted in significantly greater F2-isoP and 7-
ketocholesterol levels in fibroblasts from apoD knockout mice, compared to those 
from the wild type mice. No significant difference in cholesterol and 24-
hydroxycholsterol levels were detected between wild type and apoD knockout 
fibroblasts, consistent with the reported neuron-specific localization of cholesterol 
24-hydroxylase (Russell 2000). 
 Besides kainate lesions, an increase in apoD levels has also been 
detected in the brain in neurodegenerative conditions such as Alzheimer's 
disease (Terrisse et al. 1998; Thomas et al. 2003), Niemann–Pick type C disease 
(Suresh et al. 1998) and prion disease (Dandoy-Dron et al. 1998). It is possible, 
in view of the present findings, that apo D might play a similar role in 
sequestering arachidonic acid and cholesterol, in the brain tissue in these 
conditions. Further studies are necessary to study signaling mechanisms that 

























 The brain is the organ with the second highest concentration of lipids, 
exceeded only by adipose tissue. There is increasing evidence that early 
alteration of lipid metabolism during injury may play a critical role on neuronal 
death in neurodegenerative diseases. Kainate intracerebroventricular injection in 
rat brain and kainate-treated hippocampal slice cultures are widely used as in 
vivo and in vitro models of neurodegeneration. Using these models, kainate 
treatment results in breakdown of phospholipids and accumulation of arachidonic 
acid. The increase in arachidonic acid is accompanied by increases in the level of 
the toxic lipid peroxidation product, 4-hydroxynonenal, suggesting that altered 
phospholipid metabolism and lipid peroxidation could play a major role in 
neuronal death after kainate excitotoxicity.  
 Beside phospholipids, alterations in other major membrane lipids such as 
cholesterol and ceramide have been implicated in many neurological diseases 
such as AD, PD or stroke. However, the role of misregulation of cholesterol and 
ceramide metabolism in neurodegeneration is poorly understood. The present 
study was carried out to elucidate the dysregulation of cholesterol and ceramide 
metabolism after kainate injury. The role of apoD in modulation of kainate-
induced changed levels of lipid oxidative products and neurodegeneration was 
also elucidated. 
 Increased immunolabeling to cholesterol and the oxysterol biosynthetic 
enzyme, cholesterol 24-hydroxylase, was observed in the rat hippocampus after 
kainate lesions. This was accompanied by increased levels of cholesterol, 24-
hydroxycholesterol (product of cholesterol 24-hydroxylase enzymatic activity) and 
7-ketocholesterol in homogenates of the degenerating hippocampus, as detected 
by gas chromatography / mass spectrometry (GC/MS) in vivo and in vitro.  
 The in vitro results suggest that the increased cholesterol and oxysterols 
in brain tissue after kainate injury may be a consequence of increased 
cholesterol synthesis and cholesterol 24-hydroxylase expression in the 
degenerating brain tissue, and not only or primarily uptake from the bloodstream. 
In order to determine the possible neurotoxicity of oxysterol on hippocampal 
neurons, the hippocampal slices were treated with different concentrations of 24-
hydroxycholesterol. The results showed that the lower concentration of 24-
hydroxycholesterol (15 µM or ~7.2 ng/mg in normal tissue) was not toxic to 
hippocampal neurons, whereas the higher concentration (50 µM or ~26.2 ng/mg 
in kainate-treated tissue) was neurotoxic. These suggest that the level of 24-
hydroxycholesterol encountered in vivo after kainate injury was sufficient to 
cause neuronal damage. Hippocampi from rats or organotypic slices that had 
been treated with kainate plus lovastatin showed significantly lower levels of 
cholesterol, 24-hydroxycholesterol, and 7-ketocholesterol, compared to those 
that had been treated with kainate only.  
 Lovastatin also modulated hippocampal neuronal loss after kainate 
treatment, in vivo and in vitro. Together, the above findings suggest alterations in 
cholesterol metabolism after neuronal injury may be induced by kainate. 
Increased brain cholesterol synthesis and oxysterol formation play a role in 
propagation of neuronal death after kainate injury, and brain permeable statins 
such as lovastatin could have a neuroprotective effect by limiting the oxysterol 
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levels in brain areas undergoing neurodegeneration. 
 An increased ceramide level has also been shown in the kainate-injured 
brain by lipidomic analysis. Ceramide accumulation derives from a biosynthsis or 
from breakdown of sphingomyelin. In this study, increased expression of SPT, 
the first enzyme in the ceramide biosynthetic pathway was shown in reactive 
astrocytes of the hippocampus after kainate injections. The increase in enzyme 
expression was paralleled by increased SPT enzyme activity in the hippocampus 
at two weeks post-kainate injection. In vitro ESI/MS studies showed that 
treatment of hippocampal slice cultures with the SPT inhibitors ISP-1 and L-
cycloserine modulated increases in 16:0, 18:0 and 20:0 ceramide species. A 
possible effect of ceramide biosynthesis in kainate injury was also investigated. 
Neuronal injury was determined by quantitation of MAP2 immunostaining of 
viable neurons in CA fields of hippocampal slices, and by assay of LDH released 
into the culture. Treatment of hippocampal slices with SPT inhibitors partially 
reduced kainate-induced cell death. The above findings indicate changes in 
another major membrane lipid, ceramide, after kainate-induced neuronal injury. 
They also suggest that increased SPT activity and resulting accumulation of  
ceramide might contribute to neuronal injury after kainate excitotoxicity. 
 These finding suggest that the decreased phospholipids, increased lipid 
peroxidation, arachidonic acid, ceramide biosynthesis and cholesterol synthesis 
are involved in the neuronal injury induced by kainate. Prevention of these lipid 
changes may confer neuroprotection. Inhibition of abnormal kainate-induced 
accumulation of cholesterol and ceramide by lovastatin and SPT inhibitors, was 
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shown to prevent neural injury. The effect of a lipocalin, apoD, on the neuronal 
injury after kainate treatment was also investigated since it can carry various 
small hydrophobic ligands such as arachidonic acid and cholesterol. A previous 
study showed a marked increase of apoD expression in the rat hippocampus 
induced by kainate (Ong et al. 1997). The present study was carried out to 
examine potential effects of apoD on neuronal survival after kainate injury. 
Addition of purified human apoD to kainate-treated hippocampal slice cultures 
resulted in reduction in neuronal death, and modulation of kainate-induced 
increases in arachidonic oxidation product (F2-isoprostanes), cholesterol, 24-
hydroxycholesterol and 7-ketocholesterol. The results showed that the 
neuroprotective effect of apoD may be due to its ability to bind arachidonic acid, 
thus resulting in reduction of lipid peroxidation products, and its ability to prevent 
the formation of neurotoxic cholesterol oxidation products by regulating 
cholesterol metabolism. Fibroblasts from apoD knockout mice showed increased 
F2-isoprostane and 7-ketocholesterol levels after hydrogen peroxide-induced 
oxidative stress, suggesting that this lipocalin may be an important antioxidant in 
the brain. No significant difference in 24-hydroxycholsterol level was detected 
between wild type and apoD knockout fibroblasts, which is consistent with the 
reported neuron-specific localization of cholesterol 24-hydroxylase. 
 Phospholipids, cholesterol and sphingolipids in the brain are indispensable. 
Interactions among their mediators are not only necessary for normal function 
and survival of neurons but also for their death. Kainate can cause excitotoxic 
neuronal death through interacting with kainic acid-type receptors in neurons, 
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which induces neuronal Ca2+ overloading. The alteration in Ca2+ homeostasis 
and its short duration may lead to the degradation of phospholipids by the 
activation of PLA2 and subsequent arachidonic acid cascade. Arachidonic acid 
sets a stage to genarate oxidative stress. Oxidative stress and kainate-induced 
abnormally accumulated ceramide may be important factors that promote the 
increased cholesterol levels in kainate-treated tissue. Studies of non-neuronal 
and neuronal cells have shown that oxidative stress and ceramide production can 
induce the accumulation of cholesterol in cells by activating sterol regulatory 
element binding protein (SREBP), a family of transcription factors regulating 
synthesis of cholesterol (Zager and Kalhorn 2000, Culter et al. 2004). Depleted 
hippocampal neurons of ceramide with ISP-1 showed inhibition effect on the 
cholesterol level (Culter et al. 2004). Oxidative stress, which alters membrane 
lipid metabolism, may result in increased amounts of ceramides and cholesterols. 
The derangements of sphingolipid and cholesterol metabolism, in combination 
with AA-induced oxidative stress may cause synaptic dysfunction and neuronal 
degeneration. 
 Taken together, these findings indicate that deleterious changes in lipid 
homeostasis and signaling may be a key factor in the onset and progression of 
pathologies of the nervous system. Beside the dysregulation of membrane 
phospholipids, the misregulation of the other two major membrane lipids, 
cholesterol and ceramide, was also found in kainate-lesioned hippocampus. 
Similar to the degraded phospholipids, abnormally accumulated cholesterol and 
ceramide after kainate injury may contribute to neuronal cell. The results are 
 104
useful for understanding the mechanism of dysregulation of lipids involved in the 
pathology of neurodegeneration (Fig. 4). Prevention of dysregulated lipid 
metabolism may confer neuroprotection and provide clues to the development of 
pharmaceutical strategies to treat neurodegenerative disorders.   
 
Figure 4. Lipid alterations after KA injury 
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 Table 1. 1. Number of cholesterol positive pyramidal neurons or cholesterol 24-
hydroxylase (CYP46) positive glial cells in field CA1 of saline or kainate-injected 
rat hippocampus 
 
  S 1D 3D 1W 2W 4W 
CHO-Neu 0 313 + 39 464 + 63 919 + 104 1018 + 145 148 + 81 
CYP46-As 0 157 + 83 619 +136 1312 + 195 1815 + 225 512 + 139 
1D, 3D, 1 - 4 W refer to 1 day or 3 day, and 1, 2 and 4 week post-kainate 
injection. CHO, CYP46, Neu, As and S indicate cholesterol staining, cholesterol 
24-hydroxylase staining, neurons, astrocytes and saline respectively. The values 
are mean ± standard deviation of number of cells / mm2 in field CA1. Four 
sections were counted in each of the four rats in each category. Results were 
analyzed by 1-way ANOVA with Bonferroni's multiple comparison post-hoc test, 
P < 0.05 was considered significant. P values < 0.05 are as follows: CHO-Neu: S 
vs 1D, 3D, 1W, 2W; 1D vs 1W, 2W; 3D vs 1W, 2W, 4W; 1W vs 4W; 2W vs 4W. 
CYP46-As: S vs 3D, 1W, 2W, 4W; 1D vs 3D, 1W, 2W; 3D vs 1W, 2W; 1W vs 2W, 








Table 1. 2. Concentrations of cholesterol, 24-hydroxycholesterol and 7-
ketocholesterol in the right hippocampus of the saline or kainate-injected rats 
 
  S 3D 1W 2W 4W 
Chol (µg/mg) 23.0 + 15.8 37.5 + 16.8 63.0 + 10.2 98.6 + 16.7 67.0 + 4.2 
24-OH-Chol (ng/mg) 7.2 + 5.4 10.8 + 3.7 26.2 + 6.3 30.1 + 4.9 7.4 + 2.8 
7-keto-Chol (ng/mg) 1.4 + 0.4 1.4 + 0.3 2.8 + 0.7 4.2 + 0.9 2.6 + 0.1 
3D, 1 - 4 W refer to 3 day, and 1, 2 and 4 week post-kainate injection. Chol, 24-
OH-Chol, 7-keto-Chol and S indicate cholesterol, 24-hydroxycholesterol, 7-
ketocholesterol and saline respectively. Data was normalized to the tissue weight 
and expressed as mean + standard deviation for four rats at each time point. 
Results were analyzed by 1-way ANOVA with Bonferroni's multiple comparison 
post-hoc test, P < 0.05 was considered significant. P values < 0.05 are as follows: 
Chol: S vs 1W, 2W, 4W; 3D vs 2W; 1W vs 2W. 24-OH-Chol: S vs 1W, 2W; 3D vs 










Table 1. 3. Effect of intraperitoneal injection of lovastatin on concentrations of 
cholesterol, 24-hydroxycholesterol and 7-ketocholesterol in the right hippocampi 
of 1 week and 2 week post-kainate-injected rats 
 
 Time kainate / saline kainate / lovastatin 
Chol (µg/mg) 1 W 67.6 + 15.6 41.6 + 16.0 * 
24-OH-Chol (ng/mg) 1 W 23.1 + 10.6 7.2 + 2.9 * 
24-OH-Chol (ng/mg) 2 W 27.2 + 7.8 11.6 + 3.0 * 
7-keto-Chol (ng/mg) 1 W 2.9 + 1.1 2.0 + 0.9 
7-keto-Chol (ng/mg) 2 W 3.8 + 0.8 1.4 + 0.2 * 
1 W, 2 W, Chol, 24-OH-Chol and 7-keto-Chol indicate 1 week, 2 weeks, 
cholesterol, 24-hydroxycholesterol and 7-ketocholesterol respectively. Data was 
normalized to the tissue weight and expressed as mean ± standard deviation. 












Table 1. 4. Effect of lovastatin on concentrations of cholesterol, 24-
hydroxycholesterol and 7-ketocholesterol in hippocampal slices 
 
  CONT KA KA/LOVA 
Chol (µg/mg) 1.56 + 0.29 2.17 + 0.11# 1.68+ 0.12* 
24-OH-Chol (ng/mg) 0.37 + 0.05 0.61 + 0.07# 0.43 + 0.09* 
7-keto-Chol (ng/mg) 0.42 + 0.06 1.27 + 0.46# 0.45 + 0.09* 
CONT, KA, KA/LOVA, Chol, 24-OH-Chol and 7-keto-Chol indicate untreated 
cultures, cultures treated with kainate plus vehicle, and cultures treated with 
kainate plus lovastatin, cholesterol, 24-hydroxycholesterol, and 7-ketocholesterol. 
Data was normalized to the weight of the slices and expressed as mean ± 
standard deviation of 3 experiments (12-16 slices were used in each treatment 
group per experiment). Results were analyzed by 1-way ANOVA with 
Bonferroni's multiple comparison post-hoc test, P < 0.05 was considered 
significant. # Significant difference compared to CONT group; * Significant 







 Fig. 1. 1.  Immunoblots of cholesterol 24-hydroxylase in the rat hippocampus. 
The antibody detects a band at ~56kDa in homogenates of both saline (S) and 
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 Fig. 1. 2. A,B: light micrographs of sections of hippocampal CA1 field from a 
saline-injected rat. A: cholesterol immnuostained section, showing little labeling in 
neurons (asterisk). B: cholesterol 24-hydroxylase immunostained section, 
showing light labeling of neurons (asterisk). C,D: sections through the affected 
CA1 field of the right hippocampus, from a rat that had been injected with kainate 
3 days earlier. C: cholesterol immunostained section, showing labeled pyramidal 
cell bodies (arrows) and diffused labeling of the neuropil (asterisk). D: cholesterol 
24-hydroxylase immunostained section, showing occasional labeling in glial cells 
(arrows) but not neurons. E,F: sections through the affected CA1 field of the right 
hippocampus, from a rat that had been injected with kainate 2 weeks earlier. E: 
cholesterol immunostained section. Labeling is present in the cell bodies and 
dendrites of pyramidal neurons (arrows). Inset: control section incubated with 
antigen (cholesterol)-absorbed antibody, showing absence of staining in 
pyramidal neurons. F: cholesterol 24-hydroxylase immunostained section, 
showing labeled glial cells (arrows). G,H: sections through the affected CA1 field 
of the right hippocampus, from a rat that had been injected with kainate 4 weeks 
earlier. There is little or no staining for cholesterol (G) or cholesterol 24-
hydroxylase (H) in the degenerating CA1 field at this time (asterisks). CTRL: 
saline-injected rat. 3D, 2W, 4W: 3 days, 2 weeks, and 4 weeks after kainate 
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Fig. 1. 3. A,B: electron micrographs of cholesterol 24-hydroxylase 
immunolabeled profiles in the hippocampus of a 2 week post-kainate-injected rat. 
A: labeled astrocyte (AS), next to an unlabeled microglial cell (M). The nucleus of 
the astrocyte contains evenly dispersed fine heterochromatic clumps, and are 
distinguished from the marginated heterochromatin in the microglial cell. F: glial 
filaments. Arrows indicate reaction product. B: astrocytic end foot (AS), on a 
blood vessel. F: glial filaments. E: endothelial cell, L: lumen of vessel. Arrows 
indicate reaction product. C,D: double, cholesterol 24-hydroxylase (C, red 
channel) and GFAP (D, green channel) immunofluorescence labeled section 
from field CA1 of a 2 week post-kainate-injected rat. The cells which are positive 
for cholesterol 24-hydroxylase (arrows in B) are also labeled for GFAP (arrows in 
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Fig. 1. 4. In vivo analyses of the effect of lovastatin on neuronal survival after 
intracerebroventricular kainate injection. A: Nissl stained sections from the 
hippocampus from representative animals. CONT, KA and KA/LOVA indicate 
saline, kainate plus vehicle, and kainate plus lovastatin injected rats. Arrows 
indicate uninjured neurons in fields CA1 and CA3. Scale = 1 mm. B: percentage 
of the CA fields that contains uninjured neurons in Nissl or MAP2 stained 
sections. A significantly greater number of hippocampal neurons is present in the 
kainate plus lovastatin (KA/LOVA) injected rats, compared to the kainate plus 
vehicle (KA) injected rats. Data is expressed as mean ± standard deviation. n = 5 
in each group. Results were analyzed by Student's t-test, *P < 0.05 was 






















Fig. 1. 5. In vitro analyses of the effect of lovastatin on neuronal survival after 
addition of kainate to hippocampal slices. CONT, KA and KA/LOVA indicate 
untreated, kainate plus vehicle, and kainate plus lovastatin treated slices. A: 
MAP2 immunostained sections from representative slices. Arrows indicate 
uninjured neurons in fields CA1 and CA3. Scale = 300 µm. B: number of MAP2 
positive pyramidal neurons in cultured hippocampal slices. Values are mean ± 
standard deviation of number of cells / mm2 in fields CA1 or CA3 (n = 6 slices in 
each group). Results were analyzed by 1-way ANOVA with Bonferroni's multiple 
comparison post-hoc test, P < 0.05 was considered significant. # Significant 
difference compared to CONT group; * Significant difference compared to KA 
group. C: effect of lovastatin on LDH activity in hippocampal slice cultures. Data 
is expressed as percentage of total LDH release (mean ± standard deviation) of 3 
experiments. Results were analyzed by Student's t-test, P < 0.05 was considered 
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 Fig. 1. 6. In vitro analyses of neurotoxic effect of 24-hydroxycholesterol on 
hippocampal slice cultures. CONT, V, 24-OHC(15), 24-OHC(50) and 7-KetoC (50) 
indicate untreated cultures, cultures treated with vehicle, cultures treated with 15 
µM 24-hydroxycholesterol, cultures treated with 50 µM 24-hydroxycholesterol, 
and cultures treated with 50 µM 7-ketocholesterol. A: MAP2 immunostained 
sections from representative slices. Arrows indicate uninjured neurons in fields 
CA1 and CA3. Scale = 250 µm. B: number of MAP2 positive pyramidal neurons 
in cultured hippocampal slices. Values are mean ± standard deviation of number 
of cells / mm2 in fields CA1 or CA3 (n = 6 slices in each group). Results were 
analyzed by 1-way ANOVA with Bonferroni's multiple comparison post-hoc test, 
P < 0.05 was considered significant. #: significant difference compared to CONT; 
&: significant difference compared to 24-OHC(15). C: effect of 24-
hydroxycholesterol or 7-ketocholesterol on LDH activity in hippocampal slice 
cultures. Data were expressed as percentage of total LDH release (mean ± 
standard deviation) of 3 experiments. Results were analyzed by Student's t-test, 
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Table 2. 1. Number of SPT-positive neurons and astrocytes in field CA1 of
hippocampus.  
 
S, 1D, 3D, 1W, 2W, 4W indicate saline injection (2 week post-injection), 1 day, 3 
 S a 1D b 3D c 1W d 2W 
 the 
days, 1 week, 2 week, and 4 week post-kainate-injection. Values indicate mean 
number of cells / mm2 ± standard deviation. P values < 0.05 are as follows: 
Neurons: a vs b, c, d, e, f; b vs d, e, f; c vs d, e, f; d vs e, f. Astrocytes: a vs c, d, 














Neurons 941 ± 172 128 ± 66 118 ± 50 43 ± 29 0 0 
Astrocytes 0 76 ± 45 179 ± 43 433 ± 82 829 ±164 478 ± 126
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Fig. 2. 1. SPT enzyme protein level and activity after kainate lesions. A,B: 
Western blot analyses of saline or kainate-treated hippocampus. The antibody to 
SPT r cognized ngle ba t 65kDa sisten  the ex d mol r 
we the tal nit nific crease SPT enz e 
p tected t 1 and ks a ate nt,  
eated controls (B). Values indicate mean relative density of SPT to β-actin ± 
, 3D, 1W, 2W, 4W indicate saline 
jection (2 weeks postinjection); and 1 day, 3 days, 1 week, 2 weeks, and 4 
eeks post kainate injection. 
e a si nd a  con t with pecte ecula
ight of SPT2 ca ytic subu  (A). Sig antly in d ym
rotein is de  a  2 wee fter kain  treatme compared to saline 
tr
standard deviation. #: significant difference compared to saline injected controls. 
&: significant difference compared to 4 weeks post-kainate injection (P < 0.05). C: 
SPT enzymatic activity in microsomal fractions of the hippocampus. The values 
indicate mean activity ± standard deviation. #: significant difference compared to 
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Fig. 2. 2. Light micrographs of field CA1 of the hippocampus. A: SPT 
immunolabeled section from saline injected rat showing light immunoreactivity in 
pyramidal neurons (arrowheads). B,C,D: SPT immunolabeled sections from rats 
that have been injected with kainate 3 days (B), 1 week (C), and 2 weeks (D) 
earlier. Loss of labeling in neurons, but increased labeling in astrocytes (arrows) 
is observed in areas affected by kainate. E: adjacent section from the same 
animal as D incubated with antigen-absorbed antibody, showing absence of 
labeling (asterisk). F: SPT immunolabeled section from a rat that has been 
injected with kainate 4 weeks earlier, showing light labeling of glial cells (arrow). 
Abbreviations: S, 3D, 1W, 2W, 4W indicate saline injection, 3 day, 1 week, 2 


















Fig. 2. 3. A,B: SPT (A, red channel) and GFAP (B, green channel) double 
rescence labeled section of field CA1, from a rat that had been 
injected with kainate 2 weeks earlier. Cells which are positive for SPT are also 
labeled for GFAP (arrows) indicating that they are astrocytes. Scale A,B = 20 µm. 
C,D: sections immunostained for SPT from a rat that had been injected with 
kainate 2 weeks earlier, showing an immunoreactive glial cell with morphological 
features of astrocytes (C) and labeled astrocytic end feet (D) around blood vessel. 
Label is absent from endothelial cells (E). AS: astrocyte; F: glial filaments; L: 
lumen of the blood vessel. Arrows indicate immunoreaction products. Scale C,D 


































Fig. 2. 4. Mass spectrometric analyses of hippocampal slice cultures. A: changes 
 ceramide species after kainate treatment, and effects of enzyme inhibitors. 
Data are calculated as relative abundance of the various molecular species of 
ceramides (Cer) to internal standard (C19 ceramide) and normalized to protein 
concentration. Significant increases in 16:0, 18:0, 20:0 ceramide species were 
detected after kainate injury, and the increase were partially blocked by inhibitors 
to SPT (ISP-1 or LCS). B: sphingomyelin species after kainate treatment. Data 
are calculated as relative abundance of the various molecular species of 
sphingomyelin (SM) to internal standard (C12 sphingomyelin) and normalized to 
protein concentration. A non-significant trend to a decrease in 18:0 
phingomyelin species was detected after kainate treatment. No significant effect 
was observed after treatment with any of the enzyme inhibitors. Values indicate 
mean ± standard error. CONT, KA, KA/ISP-1, KA/LCS, KA/FUM and 
KA/GW4869 indicate untreated slices, kainate-treated slices, kainate plus ISP-1 
treated slices, kainate plus L-cycloserine treated slices, kainate plus fumonisin 
B1 treated slices, and kainate plus GW4869 treated slice P < 0.05 was 
considered significant. #: significant difference compared to CONT group. *: 
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Fig. 2. 5. Effect of SPT inhibitors on kainate-induced neuronal injury in 
hippocampal slice cultures. A,B: light micrographs (A) and cell counts (B) of 
MAP2 immunostained sections from untreated slices (CONT), kainate-treated 
slices (KA) or kainate plus ISP-1 treated slices (KA/ISP-1). Kainate treatment 
results in loss of labeling in neurons, and this loss was partially prevented by 
treatment with ISP-1. Arrows indicate uninjured neurons in fields CA1 and CA3. 
Scale = 300 µm. #: significant difference compared to CONT, *: Significant 
difference compared to KA (P < 0.05). C: cell counts of MAP2 immunostained 
sections from untreated slices (CONT), kainate-treated slices (KA) or kainate 
plus LCS treated slices (KA / LCS). Kainate treatment results in loss of labeling in 
neurons, and this loss was partially prevented by treatment with LCS. #: 
significant difference compared to CONT; *: significant difference compared to 
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Fig. 2. 6. Effect of SPT, ceramide synthase, and neutral sphingomyelinase 
inhibitors on kainate-induced neuronal injury in hippocampal slice cultures. 
Kainate treatment results in damage to neurons reflected by increased LDH 
activity in the culture medium, and this increase was partially prevented by 
treatment with ISP-1, LCS, and fumonisin B1. No significant effect was observed 
after treatment with GW4869. CONT, KA, KA/ISP-1, KA/LCS, KA/FUM and 
KA/GW4869 indicate untreated slices, kainate-treated, kainate plus ISP-1 treated, 
kainate plus L-cycloserine treated, kainate plus fumonisin treated, and kainate 
plus GW4869 treated slices. #: significant difference compared to CONT; *: 































Fig. 3. 1. The number of MAP2 labeled pyramidal neurons in CA field of cultured 
ippocampal slice. CONT, KA, 1, 5, 10 and 20 µg/ml apoD indicate untreated, 
ainate, and kainate plus 1, 5, 10 and 20 µg/ml final concentrations of apoD 
eated slices. The values are mean ± standard deviation of number of cells / 
mm2 in CA field. Results were analyzed by 1-way ANOVA with Bonferroni's 
multiple comparison post-hoc test. P < 0.05 was considered significant. * 
Significant difference compared to CONT group; # Significant difference 

















































































































Fig. 3. 2. A: effect of apoD on neuronal survival after addition of kainate to 
ippocampal slices. MAP2 immunostained sections from representative slices. 
and 
A/apoD indicate untreated, kainate, kainate plus apoD treated slices. Scale = 
00 µm. B: effect of apoD on LDH release in hippocampal slice cultures. CONT, 
A and KA/apoD indicate untreated, kainate, and kainate plus apoD treated 
lices. The values are mean ± standard deviation of percentage of total LDH 
lease. Results were analyzed by 1-way ANOVA with Bonferroni's multiple 
omparison post-hoc test. P < 0.05 was considered significant. * Significant 




















































































The number of MAP2 labeled pyramidal neurons in CA field of cultured 
hippocampal slice. CONT, KA, apoD, BLG and apoD/Ab indicate untreated, 
kainate, kainate plus apoD, kainate plus beta-lactoglobulin, kainate plus apoD 
and antibody to apoD treated slices. The values are mean ± standard deviation of 
number of cells / mm2 in CA field. Results were analyzed by 1-way ANOVA with 
Bonferroni's multiple comparison post-hoc test. P < 0.05 was considered 
significant.  
































































Fig. 3. 4. Effect of apoD on F2-isoprostanes (A), cholesterol (B), 7-
etocholesterol (C) and 24-hydroxycholesterol (D) levels in cultured hippocampal 
slices. CONT, KA and KA/apoD indicate untreated, kainate, and kainate plus 
apoD treated slices. Data was normalized to the weight of the slices and 
expressed as mean ± standard deviation of 3 experiments (12-16 slices were 
used in each treatment group per experiment). Results were analyzed by 1-way 
ANOVA with Bonferroni's multiple comparison post-hoc test. P < 0.05 was 
considered significant. * Significant difference compared to CONT group; # 





































Fig. 3. 5. Effect of hydrogen peroxide on F2-isoprostanes (A), cholesterol (B), 7-
etocholesterol (C) and 24-hydroxycholesterol (D) levels in cultured fibroblasts 
from wild type and apoD knockout mice. CONT, WT and apoD KO indicate 
untreated control, cultured fibroblasts from wild type and apoD knockout mice. 
Data are expressed as mean ± standard error of concentrations per 1 x 106 cells. 
Results were analyzed by Student's t-test, P < 0.05 was considered significant. * 
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